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Abstract 
The worldwide prevalence of obesity and metabolic disease is increasing at an 
exponential rate and current projections provide no indication of relief.  This growing 
burden of obesity-related metabolic disorders, including type 2 diabetes mellitus 
(T2DM), highlights the importance of identifying how lifestyle choices, genetics and 
physiology play a role in metabolic disease and place obese individuals at a greater risk 
for obesity-related complications including insulin resistance (IR).  This increased risk of 
IR, which is characterized by a decreased response to insulin in peripheral tissues 
including adipose tissue (AT) and liver, is associated with a chronic, low grade 
inflammatory state; however, the causative connections between obesity and 
inflammation remains in question.  Experimental evidence suggests that adipocytes and 
macrophages can profoundly influence obesity-induced IR because adipocyte dysfunction 
leads to ectopic lipid deposition in peripheral insulin sensitive tissues, and obese AT is 
characterized by increased local inflammation and macrophage and other immune cell 
populations.  Attempts to delineate the individual roles of macrophage-derived pro-
inflammatory cytokines, like tumor necrosis factor alpha (TNF-α) and interleukin-1 beta 
(IL-1β), have demonstrated causative roles in impaired systemic insulin sensitivity, 
adipocyte function and hepatic glucose and lipid metabolism in obese animal models.  
Thus, the attenuation of macrophage-derived inflammation is an evolving area of interest 
to provide insight into the underlying mechanism(s) leading to obesity-induced IR.  
  Thus, in the first chapter of this thesis, I describe experiments to refine the current 
paradigm of obesity-induced AT inflammation by combining gene expression profiling 
 viii 
with computational analysis of two anatomically distinct AT depots, visceral adipose 
tissue (VAT) and subcutaneous adipose tissue (SAT) to address whether the 
inflammatory signature of AT is influenced by diet-induced obesity (DIO).  Microarray 
and qRT-PCR analysis data revealed that DIO mouse SAT is resistant to high fat diet 
(HFD)-induced inflammation and macrophage infiltration, and our data support the 
current model of obesity-induced visceral adipose tissue macrophage (VATM) 
enrichment.  Our data demonstrated robust increases in VAT pro-inflammatory cytokine 
expression, which are consistent with the significant increases in macrophage-specific 
gene expression and consistent with previous reports in which VAT inflammation is 
enhanced and attributed to classically activated (M1) macrophage infiltration.  However, 
these data are only observed relative to the expression of invariant housekeeping gene 
expression. When M1-specific genes are expressed relative to macrophage-specific 
standards like F4/80 expression, these inflammatory makers are unchanged.  These data 
indicate that the changes in the overall inflammatory profile of DIO mouse VAT is 
because of quantitative changes in adipose tissue macrophage (ATM) number and not 
qualitative changes in activation state.  These observations are consistent with the idea 
that infiltrating ATMs may have roles other than the previously described role in 
mediating inflammation in obese adipose tissue 
 Hepatic IR occurs partly as a consequence of adipocyte dysfunction because the 
liver becomes a reservoir for AT-derived fatty acids (FAs), which leads to obesity-related 
non-alcoholic fatty liver disease (NAFLD).  In the second part of my thesis, I used 
clodronate liposome-mediated macrophage depletion to define the role of macrophages in 
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hepatic lipid metabolism regulation.  We discovered that i.p. administration of clodronate 
liposomes depletes Kupffer cells (KCs) in ob/ob mice without affecting VATM content, 
whereas clodronate liposomes depletes both KCs and VATMs in DIO mice.  To this end, 
we established that clodronate liposome-mediated KC depletion, regardless of VATM 
content in obese mice, abrogated hepatic steatosis by reducing hepatic de novo lipogenic 
gene expression.  The observed reductions in hepatic inflammation in macrophage-
depleted obese mice led to the hypothesis that IL-1β may be responsible for obesity-
induced increased hepatic triglyceride (TG) accumulation.  We determined that IL-1β 
treatment increases fatty acid synthase (Fas) protein expression and TG accumulation in 
primary mouse hepatocytes. Pharmacological inhibition of interleukin-1 (IL-1) signaling 
by interleukin-1 receptor antagonist (IL-1Ra) administration recapitulated these results by 
reducing hepatic TG accumulation and lipogenic gene expression in DIO mice.  Thus, 
these data highlight the importance of the inflammatory cytokine IL-1β in obesity-driven 
hepatic steatosis and suggests that liver inflammation controls hepatic lipogenesis in 
obesity.   
To this end, the studies described herein provide new insight and appreciation to 
the multi-functional nature of macrophages and clinical implications for anti-
inflammatory therapy in obesity and NAFLD treatment. We demonstrate the 
complexities of macrophage-mediated functions in insulin sensitive tissues and a role for 
obesity-induced inflammatory cytokine IL-1β in hepatic lipid metabolism modulation, 
which is reversed via IL-1Ra intervention.  The use of anti-inflammatory therapy to 
ameliorate obesity-associated NAFLD was perhaps the most important contribution to 
 x 
this body of work and is full of promise for future clinical application.  It is likely that the 
future of therapeutics will be multi-faceted and combine therapeutic approaches to 
enhance glucose tolerance and overall health in obese, IR and T2DM patients.   
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1.1.  Obesity and Diabetes 
Obesity has become a global epidemic that threatens to overwhelm both 
industrialized and developing countries.  According to the World Health Organization 
(WHO), greater than 1 billion adults are overweight and more than 300 million are obese 
worldwide (214).  Recent projections anticipate that 86.3% of all American adults will 
become overweight or obese by the year 2030 (249).   This growing burden of obesity 
and its co-morbidities will overwhelm our nation’s health care expenditure, with 
projections upwards of 900 billion dollars in the year 2030, which accounts for 15-20% 
of the total health care costs (249).  This expenditure is related to the imposing cost of 
treatment of obesity and co-morbidities, coined the metabolic syndrome (MS).  MS most 
commonly consists of four pathogenic states: T2DM, cardiovascular disease (CVD), 
dyslipidemia and hypertension (77, 175, 214, 243).  The growing body of evidence 
clustering these pathologies together suggests obesity as a common pathogenic link that 
acts as both a principal and causative component of the MS (246).  It is also important to 
highlight the intimate association of obesity with IR, which is characterized by a 
decreased response to insulin in peripheral tissues including AT, liver and muscle.  
Interestingly, not all obese individuals are IR, which is a long-time conundrum in 
metabolic disease research (82).  Thus, to control the rise in T2DM, we must first 
understand its causes at the molecular level, highlighting the importance of identifying 
how environmental factors, lifestyle choices, genetics and physiology play a role in 
metabolic disease and place obese individuals at a greater risk for obesity-related 
complications including IR.  
 3 
The ever growing fast-food industry and a reduced need for physical labor in 
Westernized countries has given rise to obesity, partially because of increased 
accessibility to more energy-dense, nutrient poor food.  The Western diet is primarily 
composed of calorically dense food with a relatively high carbohydrate and saturated fat 
content.  This diet combined with a sedentary lifestyle creates an imbalance between 
energy intake and energy expenditure (EE), thus leading to increased adiposity.  Excess 
energy from increased food consumption is stored within AT, which is an essential and 
metabolically active endocrine organ that can store and release energy to coordinate 
important biological processes (discussed in section 1.6.).   
The postprandial state is a significant contributing factor to the MS and diabetic 
complications.  Upon carbohydrate load, blood glucose levels rise and pancreatic β-cells 
release copious amounts of insulin into circulation to reduce blood glucose levels. This 
function of insulin is mediated primarily on 3 major insulin target tissues: liver, muscle 
and AT.  In muscle and AT, insulin promotes the facilitated uptake of glucose and its 
conversion to glycogen and TGs for storage.  However, in the liver, the function of 
insulin is to suppress hepatic glucose production by inhibiting select pathways that 
control glycogenolysis and gluconeogenesis while stimulating glucose storage as hepatic 
glycogen.  The failure of insulin to elicit a response on these peripheral and vital target 
tissues results in the disruption of stable blood glucose levels, leading to IR and 
ultimately T2DM.  These and other topics will be discussed in the sections below. 
  
 4 
1.2. The Discovery of Insulin 
One of the greatest biomedical advances of the twentieth century was the 
discovery of insulin in 1921 (32).  The discovery of insulin has revolutionized our ability 
to maintain glucose homeostasis in Type 1 diabetics (T1DM) and has driven molecular 
investigations into the insulin signaling pathway, which has led to the development of 
therapeutics to prevent and treat T2DM.  The molecular mechanisms and processes that 
are responsible for insulin action as well as its resistance in different organ systems have 
been investigated at both the molecular and physiological level.  These molecular 
processes provide a foundation for the data herein and will be described in detail below.   
Insulin is a small peptide hormone produced and secreted by pancreatic β-cells 
that is best known for its function to regulate blood glucose concentrations by signaling 
to its target tissues: muscle, liver and AT.  Insulin suppresses hepatic glucose production 
(gluconeogenesis) and promotes glycogen synthesis (glycogenesis) and storage in both 
liver and muscle.  These glucose metabolism and homeostasis pathways are described in 
section 1.4.  Insulin also mediates TG synthesis and storage in the liver and AT while 
promoting amino acid storage in muscle (257).  Therefore, in healthy individuals, the 
ability of insulin to balance glucose influx and output to and from the circulation by 
stimulating glucose uptake, utilization, and liberation for biological processes is essential.   
Diabetes, commonly associated with obesity, is a disruption in the ability of 
insulin to reduce blood glucose concentrations and is clinically defined by the WHO as a 
fasting blood glucose levels  >126 mg/dL.  Although diabetes pathophysiology is diverse, 
it presents primarily as T1DM and T2DM, which both share insulin action as a common 
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denominator.  T1DM is caused by an auto-immune-mediated destruction of insulin-
producing pancreatic β-cells, which subsequently causes absolute insulin deficiency 
(257).  Thus, T1DM patients are characterized by high blood glucose levels and are 
dependent on supplemental insulin to reach normoglycemia.  In the setting of IR and 
T2DM, individuals are characteristically hyperinsulinemic, as insulin production and 
secretion by pancreatic β-cells fails to compensate for peripheral IR that typically occurs 
due to excess body weight.  Thus, at least in its early stages, T2DM is characterized not 
by insulin deficiency, but by the failure of insulin to act efficiently upon target tissues. 
However, a long-time conundrum in the field of T2DM and IR is whether 
hyperinsulinemia precedes IR or vice versa.  Transgenic mice that overexpress the human 
insulin gene developed IR subsequent to hyperinsulinemia, supporting the hypothesis that 
hyperinsulinemia might be a primary event leading to increased hepatic lipogenesis 
(described in section 1.7.2.) and the secondary development of IR (143, 151).  
While innovative treatments for insulin management in T1DM patients are 
available, the only true treatment to restore physiological glucose metabolism is by 
pancreatic β-cell or isolated pancreatic islet transplantation (184).  However, T2DM 
patients may require one or more anti-diabetic drugs such as Thiazolidinedione (TZDs) or 
exogenous insulin, and these patients can often reverse IR with these treatments and 
healthy lifestyle intervention.  Thus, our understanding of the complexities of insulin 
signaling are critical, and enhancing this knowledge will significantly limit the expansion 
of the current obesity epidemic and the consequent rise in T2DM.   
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1.3. Insulin Signaling 
For insulin action to occur, insulin must bind to the insulin receptor, which is a 
tyrosine kinase that undergoes a conformational change and autophosphorylation at 
multiple tyrosine residues upon stimulation (10, 127, 182).  Autophosphorylation 
increases the catalytic activity of the receptor, and the phosphorylated tyrosines recruit 
scaffolding proteins including a protein family known as insulin receptor substrates or 
IRS proteins (231, 257).  Docking of IRS proteins allows for their tyrosine 
phosphorylation by the insulin receptor and the subsequent formation of binding sites for 
Src-homology-2 (SH2) domain-containing proteins, which serves as a complex binding 
platform to initiate downstream signaling (256).  These scaffolding proteins are required 
for a complete insulin signal and serve as a docking platform for the SH2 domain-
containing regulatory subunits of phosphatidylinositol 3-kinase (PI3K) and the growth 
factor receptor bound protein 2 (GRB2) (256-257).  These two adaptor molecules 
regulate the two main conduits of insulin action: PI3K and serine/threonine protein kinase 
B (AKT/PKB) and GRB2 and the mitogen activated protein kinases (MAPKs) (231, 
256).  The PI3K/AKT pathway regulates the metabolic actions of insulin including 
glucose utilization, production and uptake, while MAPKs coordinate with PI3K to 
regulate cell growth, gene expression and differentiation (231).  The effects of these 
pathways are summarized below and in Figure 1.1. 
PI3K plays an important role in the regulation of glucose and lipid metabolism 
and the metabolic actions of insulin by mediating the phosphorylation of many substrates 
including glycogen synthase kinase 3 β (GSK3β), the Rab GTPase activating protein 
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(GAP) with a molecular weight of 160 kDal (AS160), and phosphodiesterase 3B 
(PDE3B) which are important for regulating glycogen synthesis, glucose uptake and lipid 
storage, respectively (203, 257).  PI3K via AKT activation also regulates the Forkhead 
box O-class (FOXO) family of transcription factors that requires phosphorylation and 
translocation to and from the nucleus to either activate transcription of target genes 
within the nucleus or inhibit gluconeogenesis and adipocyte differentiation when 
excluded from the nucleus (154, 190).  Insulin also activates extracellular-signal 
regulated kinases (ERKs) via the GRB2 arm of insulin action which are involved in 
mitogenesis (203).  Importantly, insulin also promotes lipid storage and inhibits AT 
lipolysis by promoting fatty acid re-esterification and TG synthesis as well as inhibiting 
fatty acid transport.  These mechanisms of insulin-mediated lipid metabolism are relevant 
to Chapter 3 and will be described in detail in sections 1.5.1. and 1.7.2. in regards to AT 
and hepatic lipid metabolism, respectively (203). 
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Figure 1.1 Nodes of insulin signaling.  The metabolic pathways regulated by insulin 
action require insulin binding to the insulin receptor (IR) which activates its receptor 
tyrosine kinase activity and stimulates insulin receptor substrate adaptor protein 1 
(IRS1/2) tyrosine phosphorylation. Tyrosine phosphorylated IRS1 serves as a docking 
substrate for phosphatidylinositol 3-kinase (PI3K) and growth factor receptor bound 
protein 2 (GRB2) to activate the protein kinase B (AKT) and extracellular-signal 
regulated kinase (ERK1/2) branches of insulin-mediated metabolic signaling. AKT and 
ERK activation regulates the processes indicated in the diagram. Some of these processes 
are cell type specific such as the stimulation of glycogen synthesis in muscle, TG 
synthesis in AT, glucose uptake in AT and muscle and the inhibition of hepatic 
gluconeogenesis. 
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1.4. Regulation of Glucose Homeostasis 
A primary survival mechanism of mammals is maintaining blood glucose 
concentration homeostasis because glucose is utilized as a primary fuel source for all 
eukaryotic cells and is required to generate energy for physiological functions.  Blood 
glucose concentrations must be tightly controlled by balancing the rate of glucose entry 
and removal from the circulation (119).  The distribution of circulating glucose is 
complex and requires various tissues to uptake, process and store glucose to ensure 
adequate glycogen pools when energy is in demand.  These processes are under strict 
hormonal control by the glucoregulatory hormones glucagon and insulin, which are 
hormones derived from pancreatic α- and β-cells, respectively (illustrated in Figure 1.2). 
These hormones have opposing functions as glucagon is a potent stimulator of hepatic 
glucose production whereas insulin both inhibits glucose production and facilitates 
glucose uptake into skeletal muscle and AT by stimulating the translocation of glucose 
transporter 4 (GLUT4), a transport protein that shuttles glucose across the cell surface, 
thus reducing plasma glucose concentrations (17, 97, 171).  Other pancreatic and incretin 
hormones from the gut including amylin,  glucagon-like peptide 1 (GLP-1) and other 
glucocorticoids also regulate circulating glucose concentrations (246). 
In normal physiology, circulating glucose comes from intestinal food absorption 
and hepatic glycogenolysis and gluconeogenesis. After feeding, the most readily 
available circulating glucose is derived from intestinal absorption and is utilized by 
peripheral tissues such as skeletal muscle, brain, red blood cells and AT (171).  The 
major cellular mechanism to remove exogenous circulating glucose is insulin-stimulated 
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glucose transport into skeletal muscle via GLUT4, where it can be stored as glycogen, a 
polymerized storage form of glucose, or oxidized to produce energy immediately upon 
transport into the muscle (97, 193).  Insulin-stimulated glucose transport into AT via 
GLUT4 also occurs upon glucose load, although to a much lesser degree than skeletal 
muscle.  However, downregulation of GLUT4 expression in obese mouse AT as well as 
humans has a profound impact on glucose homeostasis and IS (68, 104).  Excess glucose 
is also transported through the portal vein into the liver by non-insulin-dependent glucose 
uptake via glucose transporter 2 (GLUT2).  This uptake can initiate a number of 
processes including glycogenesis, which is the process of glycogen synthesis (171).  
Other sources of circulating glucose come from hepatic processes, which maintain blood 
glucose levels during periods of prolonged fasting and are stimulated by glucagon.  
During the first 8-12 hours of a fast, glucose is primarily produced by glycogenolysis, or 
the breakdown of glycogen to release glucose (119).  During periods of prolonged 
fasting, the liver produces glucose via gluconeogenesis, which is the metabolic process 
by which the liver synthesizes glucose de novo from non-carbohydrate sources such as 
pyruvate, lactate, glycerol, and amino acids (119, 171).   
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Figure 1.2.  Insulin suppresses hepatic glucose production by direct and indirect 
mechanisms.  Hepatic glucose metabolism is under strict hormonal control by the 
glucoregulatory hormones glucagon and insulin. These hormones have opposing 
functions as glucagon is a potent stimulator of hepatic glucose production (HGP), 
whereas insulin both inhibits HGP and facilitates glucose uptake into skeletal muscle and 
AT.  Insulin stimulates glycolysis and represses gluconeogenesis and glycogenolysis 
pathways where as glucagon is a potent stimulator of gluconeogenesis and 
glycogenolysis in fasted conditions.  In IR, insulin has impaired ability to suppress AT 
lipolysis and glucagon secretion by pancreatic α-cells causing increased gluconeogenesis. 
Insulin inhibition of glycogenolysis is also impaired.  Thus, both hepatic and peripheral 
IR results in abnormal glucose production by the liver. 
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The inhibition of de novo glucose synthesis in the fed state is critical to avoid a 
circulatory glucose overload.  The insulin-mediated inhibition of the hepatic glucose 
production and release is accomplished by blocking gluconeogenesis and glycogenolysis 
pathways.  Insulin directly regulates the expression of genes encoding hepatic enzymes 
required for gluconeogenesis and glycolysis, which is the energy releasing process of 
converting glucose to ATP and pyruvic acid.  Insulin accomplishes this inhibition by 
post-translational modifications to the enzymes, thus controlling their activity (183, 202).   
Insulin also inhibits the transcription of the gene encoding phosphoenolpyruvate 
carboxylase (PEPCK), the enzyme required for the rate limiting step in gluconeogenesis, 
as well as other enzymes fructose-1,6-bisphosphatase (F6P2) and glucose-6-phosphatase 
(G6Pase) by the liver (228).  Insulin also upregulates the transcription of the genes that 
are necessary for glycolysis including glucokinase (GK) and pyruvate kinase (PK) (202).    
Insulin mediates its regulation of lipid metabolism mainly via the promotion of 
lipid storage within adipocyte lipid droplets (LDs) and lipolysis inhibition.  However, 
actions of insulin must be coordinated in both AT and liver to enhance the synthesis of 
TGs, which are the primary source and storage form of lipid in humans that allow energy 
to be stored until times of caloric or energy demand (33).  It is within the adipocyte LD 
that TGs are stored in healthy individuals; however, this storage capability is upregulated 
in DIO mice and humans.  Although AT has the capability to expand to store excess 
nutrients within LDs without molecular repercussions, excessive nutrient overload 
subsequently leads to dysregulation of the lipolysis-lipogenesis balance in adipocytes, 
thus increasing ectopic lipid stores in the liver and other peripheral tissues (33, 207).  In 
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the liver, hepatocytes are a major site of de novo lipogenesis (DNL) or FA synthesis as 
well as the overall lipogenesis pathway involving FA esterification with glycerol 3-
phosphate (G3P) to form triacylglycerol, or TGs (discussed in section 1.7.2.) (33, 35).  
Studies using non-metabolizeable glucose analogues in hepatocytes, adipocytes, and even 
pancreatic β-cell lines have provided evidence that glucose must be actively metabolized 
to affect the transcription of genes involved in these glucose-responsive pathways, 
including lipogenesis (69).   
Major impact was made in T2DM therapeutics with the discovery of novel anti-
diabetic drugs that improve systemic IS by reducing circulating blood glucose 
concentrations.  One such class of drugs is the TZDs, including rosiglitazone and 
pioglitazone, which function to enhance glucose disposal in skeletal muscle as well as 
insulin-mediated hepatic gluconeogenesis inhibition (192, 209).  Thus, TZDs successfully 
improve glycemic control via insulin sensitization in humans undergoing treatment. 
These drugs target the peroxisome proliferator-activated receptor (PPAR) family of 
nuclear receptors, specifically the PPARγ isoform, which is most highly expressed in 
adipocytes.  PPARγ is the master regulator of adipogenesis, or the development of fat 
cells from preadipocytes otherwise known as adipocyte differentiation.  Importantly, 
PPARγ is intimately involved in energy homeostasis and is required to regulate essential 
glucoregulatory and lipogenic genes (GK, GLUT4, lipoprotein lipase (LPL), adipocyte 
fatty acid transporter protein, and fatty acid synthase (Fasn)), supporting the increased IS 
in TZD-treated T2DM humans and mice (156, 209).  However, because these drugs 
promote adipogenesis, a side effect of treatment is weight gain from increased AT mass, 
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fluid retention and edema, which is a possible complication with obese patients that are 
also suffering from CVD (209).  Other therapeutic options are the use of high doses of 
salicylates or aspirin, or non-steroidal anti-inflammatory drugs (NSAIDs), which have 
been used in obese IR rodents such as the Zucker fa/fa rat or the ob/ob leptin-deficient 
mouse (described in section 1.5.2.) (266). These drugs reduce fasting blood glucose with 
significant improvements in glucose tolerance and insulin signaling (266).  Salsalate, an 
NSAID in the class of salicylates, lowers fasting blood glucose in humans with impaired 
glucose tolerance (71). The mechanism whereby salsalate mediates its metabolic effects 
on IS remains elusive, although it is likely due to alterations in hepatic IS by regulating 
glucose production or insulin clearance and it’s affects on NFkB activity (discussed in 
section 1.10.2.) (71). 
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1.5. The Role of Adipose Tissue 
In humans and rodents, there are two distinct types of AT: brown adipose tissue 
(BAT) and white adipose tissue (WAT).  BAT is a thermogenic organ that is comprised 
of many mitochondria and functions to maintain thermal homeostasis by oxidizing FAs to 
generate heat (244).  BAT has significant control over the body’s total energy 
expenditure (EE) and metabolic rate, and expressing uncoupling protein-1 (UCP-1).  
UCP-1 uncouples proton pumping and ATP production from oxidative phosphorylation 
by creating a proton leak to produce heat by the process of nonshivering thermogenesis 
(72-73). Thus, dysfunctional BAT can profoundly impact metabolism and play a role in 
obesity and the MS by reducing EE.  WAT, a considerable focus of this thesis and will 
herein be referred to as AT, functions as the primary reservoir of the human body for 
energy and plays a central role in the development of IR in obesity.   
AT is highly responsive to insulin and exerts profound control over whole body 
glucose metabolism (77, 214).  The ability to sequester FAs from circulation and 
synthesize TGs de novo from glucose is a significant contribution of adipocytes within 
AT to maintaining metabolic homeostasis.  The significance of AT plasticity and storage 
capability is reinforced by the observation that a lack of normal and functioning AT, a 
medical condition known as lipodystrophy, increases circulating TGs and free fatty acid 
(FFA) concentrations, which are both causal for IR in mice and humans (discussed in 
section 1.10.2.) (77, 88, 150).  Considering that both obese and lipodystrophic humans 
and mice both exhibit severe IR and dyslipidemia, it is a lucid fact that excess fat 
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contributes to the pathology of the MS and that normal AT is required for the 
maintenance of systemic glucose and lipid homeostasis.  
 
1.5.1.  Lipid Metabolism in AT 
  AT functions as a lipid sink to buffer energy imbalances by storing energy in the 
form of TGs, which are highly concentrated neutral lipids that are comprised of a 
glycerol backbone and 3 FA moieties, in times of excess energy intake.  TGs are stored 
within adipocyte LDs, which are a single intracellular, hydrophobic organelle.  Contained 
within this dynamic structure are the building blocks for membranes and substrates for 
energy metabolism, and they thus serve as a reservoir of energy stores for times of caloric 
need (74, 247).  LDs associate with unique protein complexes that enable lipid synthesis 
into TGs via lipogenesis, which requires multiple mechanisms including fatty acid 
uptake, de novo FA synthesis and esterification into TGs (33, 201).   Although a fraction 
of whole-body TG synthesis is observed in AT, the process of lipogenesis is primarily 
executed in the liver during very low-density lipoprotein (VLDL) production (discussed 
in section 1.7.2.).  However, FA mobilization via breakdown of these TGs that are stored 
within the LD is a process unique to adipocytes and is known as lipolysis (201).  One 
hypothesis in obesity, is dysregulation of the lipogenesis-lipolysis balance in AT 
stemming from AT expansion and the subsequent immune cell infiltration and cytokine 
production and secretion results in the observed metabolic and cardiovascular 
complications (discussed in section 1.6.) (201).   
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Excess FAs and other circulating lipids are a driving force for inflammation and 
are toxic to cells, however, lipolysis-mediated FA mobilization when glucose is limited is 
important to deliver energy to peripheral tissues (14, 197).  Adipocytes liberate FAs by 
activating adipose triglyceride lipase (ATGL), hormone-sensitive lipase (HSL) and 
monoglyceride lipase (MGL) within adipocytes in a stepwise fashion to sequentially 
hydrolyze TGs into diacylglycerol (DAG), monoacylglycerol, and glycerol, releasing a 
FA moiety at each step (116).  HSL and ATGL are key enzymes that are required for 
normal AT function, which has been verified by knockout (KO) mouse studies.  HSL KO 
mice have reduced AT mass, and these mice as well as ATGL KO mice both have a 
decreased lipolytic response to catecholamines in vivo and in vitro (78-79, 248).  
Classically, the canonical pathway to activate lipolysis is the interaction of 
catecholamines with β-adrenergic receptors on adipocytes, which activates adenylate 
cyclase to increase cellular cAMP levels and ultimately stimulate lipolytic FA breakdown 
(270).  Alternatively, lipolysis can be activated by the ERK signaling cascade, natiuretic 
peptide, growth hormone, and in the context of obesity and IR, cytokine signaling plays 
an important role in FA mobilization (described in section 1.10.1.) (24, 270). 
 
1.5.2. Adipokine and Cytokine Secretion 
Functional AT is necessary for the synthesis and secretion of endocrine hormones 
called adipokines, such as leptin and adiponectin, which enhance IS and display impaired 
expression in lipodystrophic humans and mice (88, 110).  Leptin is a hormone that is 
secreted by adipocytes and acts in the brain to decrease food intake and promote EE (120, 
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147).  Leptin stimulates FA oxidation and prevents lipid accumulation in non-adipose 
tissues, including muscle, liver and pancreas (146-147).  The role of leptin in energy 
homeostasis is demonstrated by the extreme obesity and hyperphagia (over-eating) of the 
ob/ob mouse, which lacks leptin (269). The db/db mouse has a mutation within the leptin 
receptor resulting in an absence of activity and has an obese phenotype with hyperphagia, 
similar to the ob/ob mouse (126).  The key site of leptin action in regulating energy 
balance is the central nervous system (CNS) via regulation of Janus kinase (JAK)-signal 
transducers and activators of transcription (STAT) intracellular signaling pathway by 
STAT3 phosphorylation (120).  The positive correlation of increased adiposity and 
elevated leptin suggests that obesity not only to leads to IR, but also leptin resistance 
(152).  Another adipokine that is exclusively secreted from AT is adiponectin, which 
functions to regulate whole body IS and circulating levels are decreased in both obese 
and IR humans and mice (95-96).  Adiponectin KO mice present with reduced hepatic IS 
(156).  Interestingly, transgenic mice overexpressing adiponectin on the ob/ob 
background results in increased IS despite massive obesity, which may be explained by 
increased adipogenesis and enhanced ability to expand subcutaneous AT (SAT) by 
redistributing TG deposition from hepatocytes and muscle cells to adipocytes as well as 
increased expression of PPARγ target genes in AT (113).     
In obesity and IR, AT is also a potent source of pro-inflammatory cytokines such 
as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and monocyte chemoattractant 
protein 1 (MCP-1), all of which are upregulated in obese humans and mice (41, 108, 
237).  These cytokines contribute to increased immune cell trafficking and AT infiltration 
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and are hypothesized to be causal to the adipocyte dysfunction observed in obesity (24, 
41).  TNF-α, IL-1β and other important cytokines will be discussed further in section 
1.10.1., but the role of MCP-1 in AT is quite paradoxical.  With increasing obesity and 
adipocyte enlargement (hypertrophy), MCP-1 expression and secretion in AT is increased 
(204).  As a potent chemoattractant, MCP-1 secretion increases macrophage infiltration 
into AT, thus contributing to the chronic state of low-grade inflammation in obesity.  In 
agreement with this, studies from our laboratory demonstrate MCP-1 treatment of ob/ob 
mouse VAT explants induces macrophage cell division and decreases in ATM 
proliferation within the VAT of MCP-1 KO mice, independently of monocyte 
recruitment (1).  Surprisingly, other studies report that MCP-1 KO mice are IR when fed 
a high fat diet (HFD), and adoptive transfer experiments with MCP-1 KO monocytes 
reveal insignificant reductions in immune cell trafficking (100, 170).  However, mice 
deficient in the receptor for MCP-1, the C-C motif chemokine receptor-2 (CCR2) show 
significant improvements in AT inflammation, glucose homeostasis and IS, suggesting it 
is the receptor that is responsible for the inflammatory phenotype and that other factors 
impact immune cell trafficking into obese AT (166, 251).  Together, these observations 
provide evidence that functional AT is necessary and required to maintain normal IS and 
glucose homeostasis. 
 
1.5.3. AT distribution 
AT contains adipocytes as well as the stromal vascular fraction (SVF), which is 
comprised of immune cells, endothelial cells, fibroblasts, preadipocytes and other non-
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adipocyte cells.  Although cross-talk among these cells facilitates the function of AT, the 
anatomical location of AT depots plays an important role in whole-body metabolism.  It 
is well known that AT distribution is essential to regulating the metabolic state of humans 
and rodents.  In human obesity, body type and specific differences in fat distribution 
reveal differential inflammatory profiles.  Visceral AT (VAT) is associated with more 
adverse risk factors than SAT for the MS because its anatomical location within the 
peritoneal cavity allows for the release of adipokines, FFAs, cytokines, and other 
endocrine hormones directly into the portal vein, which affects hepatic metabolic 
functions and ultimately systemic IS (61).  Unlike the VAT depot, evidence from both 
human and animal studies has suggested a protective role for SAT.  In humans, increased 
subcutaneous fat in the lower extremities is associated with a decreased risk of disturbed 
glucose metabolism and dyslipidemia independent of VAT expansion (218).  In both 
humans and rodents, TZD treatment increases total fat mass, mostly in subcutaneous fat 
stores, resulting in significant improvements in IS (149).  SAT transplantation into 
visceral compartments in mice reduces body weight and total fat mass and improves 
glucose metabolism, suggesting that SAT may be intrinsically different from VAT in 
beneficial ways (235). 
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1.6. Adipose Tissue Expandability Theory and Insulin Resistance 
Although AT functions primarily as a storage depot, the expandability hypothesis 
states that AT has a defined expansion limit (243).  AT can expand by hyperplasia 
(increased cell number), but it is adipocyte hypertrophy that protects other tissues from 
circulating lipids and is key to maintaining IS.  As described above, the hormonal 
regulation of the lipolytic-lipogenic balance in AT is pertinent to IS.  Thus, the uptake of 
substrates for storage coupled with the timed release of FAs to non-adipose organs for 
oxidization as an energy source must be tightly controlled to avoid the molecular 
repercussions caused by dysregulated expansion (77).  The effects of nutrient overload on 
AT expansion and systemic IS are described below and are illustrated in Figure 1.3.  
In lean, healthy individuals, insulin-stimulated glucose uptake is normal and AT 
can expand to buffer excess nutrients.  However, in a state of over nutrition and dietary 
excess, the AT is under high metabolic stress and once the cell ‘expansion limit’ is 
exceeded, hypertrophic adipocytes “spillover” releasing copious amounts of FFAs into 
the circulation.  This rise in circulating FFAs and subsequent ectopic lipid deposition 
within IS and insulin-producing tissues in the periphery leads to a systemic disruption of 
glucose metabolism and cardiac function (77, 207).  This phenomenon, known as 
lipotoxicity, adversely affects non-adipose tissues leading to cellular dysfunction and 
apoptosis (207).  The lipotoxic hypothesis, first proposed by Robert Unger in 1995, 
illustrates that in obesity-dependent T2DM, the IR of peripheral tissues and glucose 
incompetence of β-cells are both caused by an increase in FFA delivery to both insulin 
target tissues and the islets of Langerhans within the pancreas (236).  This theory 
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parallels the expandability theory of AT in that they both present causal evidence for 
ectopic FA deposition being responsible for the IR observed in obesity (243).  Lipid 
deposition in the pancreas and islet TG accumulation results in dysregulated insulin 
secretion, pancreatic inflammation and β-cell apoptosis (207, 212).   Although skeletal 
muscle and heart are tissues with high FFA turnover and metabolism, excess 
intramyocellular accumulation of FAs and their metabolites disrupt insulin receptor 
tyrosine phosphorylation and prevent insulin-stimulated GLUT4 translocation to the 
plasma membrane (75, 207).  In the liver, lipids accumulate within hepatocytes, which 
impairs FA β-oxidation and the ability of insulin to suppress hepatic gluconeogenesis, 
thus increasing circulating glucose concentrations (171).  Hepatic TG and FFA 
accumulation also leads to NAFLD and progression to non-alcoholic steatohepatisis 
(NASH), which is characterized by the increased inflammatory response of lipid-laden 
resident liver macrophages (KCs) and hepatocyte cell death (described in section 1.7.3.) 
(129).  Thus, the adverse effects of ectopic lipids in non-adipose tissues and the 
pathogenesis of IR is partially attributed to dysregulated adipocyte metabolism and 
lipotoxicity in IS/producing tissues.  
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Figure 1.3.  Nutrient overload leads to inflammation and insulin resistance in 
adipose and peripheral tissues. In the lean state,  healthy AT efficiently stores excess 
energy as TG and expands with properly regulated insulin-stimulated glucose uptake.  In 
a state of dietary excess, the AT is under high metabolic stress and the adipocyte 
expansion limit is  reached whereby TG storage is dysregulated.  Resident and recruited 
macrophages and other immune cells are activated and hypertrophic adipocytes release 
copious amounts of inflammatory cytokines and FFAs into the circulation causing 
ectopic lipid deposition in insulin sensitive/producing tissues muscle, liver and pancreas.  
This lipotoxicity causes pancreatic β-cell failure and IR in insulin sensitive tissues in the 
periphery.  The increasing glucose, inflammatory cytokine and FA levels in the 
circulation causes the metabolic and cardiovascular complications associated with obesity 
and ultimately T2DM.  
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 1.7. The Role of the Liver 
As the main detoxifying organ of the body, the liver also plays a unique role in 
metabolic homeostasis by controlling both systemic carbohydrate and lipid metabolism.   
The liver is the major site for uptake, synthesis, storage, secretion, and catabolism of FAs 
and TGs, and other important functions including glycogen storage, plasma protein 
synthesis and hormone production.  These pathways are controlled through the 
coordinated actions of hormones circulating from the portal vein to the liver where they 
can bind their respective receptors located on the plasma membrane of hepatocytes, the 
primary cell type within the liver (217).  Other cell types are present within the lining of 
the hepatic sinusoidal walls including Kupffer cells, endothelial cells, stellate cells, 
lymphocytes and other immune cells (2, 217).  Notably, it is the hepatocyte that is 
responsible for the many functions of the liver and the two major metabolic functions 
relevant to this thesis, glucose and lipid metabolism, are intimately connected and critical 
to the understanding of the work described herein.  The molecular details of these 
metabolic functions are described in detail below and illustrated in Figures 1.4.-1.5. 
 
1.7.1. Hepatocyte glucose uptake and processing 
 As described in section 1.4., the liver produces glucose by two mechanisms: 
glycogenolysis, or the breakdown of glycogen stores and gluconeogenesis, the de novo 
synthesis of glucose from non-carbohydrate precursors.  In contrast to GLUT4, which is 
expressed in muscle and AT, insulin-independent expression and activity of GLUT2 is 
essential in the post-prandial state for hepatocytes to take up glucose for metabolic 
processes (12).  Once taken up by hepatocytes, glucose is immediately phosphorylated by 
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GK, creating G6P, a critical intermediate of hepatic glucose metabolism, trapping glucose 
inside the cell to be metabolized (Figure 1.4) (185).  The rate limiting activities of the 
enzymes PEPCK, G6Pase, and GK are required to generate G6P (185).  PEPCK catalyzes 
the conversion of oxaloacetic acid to phosphoenolpyruvate (PEP), the metabolite 
necessary to begin the conversion of (PEP) to glucose.  G6Pase however, catalyzes the 
final reaction of gluconeogenesis by dephosphorylating G6P to generate free glucose.  
This final step is shared both by gluconeogenesis and glycogenolysis as glucose must be 
phosphorylated by GK, the rate limiting enzyme for glucose utilization and the first step 
in generating G6P for the glycogen production for storage within the liver (185).  
Intracellular G6P concentrations also act within a feedback loop as an allosteric activator 
of glycogen synthase (GS), the rate-limiting enzyme of glycogen synthesis (12, 185).  In 
hepatocytes, the balance of GK and G6Pase as well as the expression levels of other 
enzymes are tightly controlled at the transcriptional level by hormones, mainly insulin, 
glucagon and glucocorticoids to maintain normoglycemia (119, 185).  Transcription 
factors including the hepatocyte nuclear factor-4α (HNF-4α), PPARα, cAMP response 
element-binding protein (CREB) and the peroxisome proliferative activated receptor-γ 
co-activator-1α (PGC-1α) all regulate enzymes involved glucose metabolism, including 
PEPCK and G6Pase (12).  PGC-1α alters gluconeogenic gene expression by directly 
binding to HNF-4α and to other transcription factors including Foxo1, the activation of 
which is dependent upon the PI3K/AKT arm of insulin action (185).  GSK3 is a 
multifunctional kinase downstream of the PI3K/AKT arm of insulin action that is 
responsible for phosphorylating GS for activating glycogen synthesis and also 
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phosphorylates sterol response element-binding protein 1c (SREBP-1c), a critical 
transcription factor involved in hepatic lipid metabolism and described in the next section 
1.7.2.         
 As described above, the metabolic state of the body dictates the fate of glucose 
utilization.  G6P is not only metabolized for glycogen synthesis in the fed state, but G6P 
is also processed by glycolysis, the ten-step energy-releasing process that metabolizes 
glucose to pyruvate with a net gain of two ATP and two NADH molecules per glucose 
molecule (12).  When ATP is in abundance and the cell no longer requires the energy 
from this process, this pathway is inhibited by a feedback loop dependent upon ATP 
concentrations (12).  The end product pyruvate is further decarboxylized to acetyl-CoA, 
which enters the intramitochondrial tricarboxylic acid cycle or acts as a substrate for de 
novo lipogenesis (DNL).  This pathway is regulated by the PI3K/AKT arm of insulin 
action and is controlled hormonally by insulin, epinephrine, and glucagon (185).  NADH, 
however, is a co-substrate for DNL and cholesterol synthesis that is provided by 
alternative G6P degradation via diversion to the pentose phosphate shunt pathway.  This 
alternative glucose metabolism links intracellular glucose and lipid metabolism providing 
evidence that any alteration in hepatic glucose uptake and processing not only affects 
hepatic and systemic glucose homeostasis, but affects hepatic and ultimately systemic 
lipid metabolism, described in the next section (1.7.2.). 
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Figure 1.4.  Glucose 6-phosphate is a metabolite that is shared by several hepatic 
pathways. Hepatic glucokinase (GK) allows for the rapid and efficient phosphorylation 
of glucose to yield glucose 6-phosphate (G6P), a key substrate in glucose metabolism.  In 
hepatocytes, G6P concentrations are determined by the balance between G6Pase and GK 
activities.  G6P is an allosteric activator of glycogen synthase (GS), but is also a key 
metabolite that can enter glycolysis. Additionally, because the major function of hepatic 
glycolysis is to provide carbons from glucose for de novo lipogenesis (DNL), G6P is also 
a determinant for this pathway and for fatty acid synthase (FAS) and acetyl CoA 
carboxylase (ACC) induction.  Adapted from Postic, et al. Diabetes Metab 30: 398-408, 
2004.
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1.7.2. Hepatic lipid metabolism 
 
Hepatic lipid metabolism is composed of a number of pathways including fatty 
acid uptake, lipogenesis, fatty acid oxidation, VLDL synthesis and secretion.  The 
metabolic breakdown of lipids begins with the ingestion of dietary carbohydrates and 
fats.  Once fats are ingested, they are emulsified by bile acids that are synthesized and 
secreted by hepatocytes and hydrolyzed by pancreatic lipases in the intestines (12).  
Intestinal enterocytes absorb, re-synthesize and package these lipids into intestinal TG-
containing chylomicrons to enter circulation through the lymphatic system (12, 217).  
These chylomicrons express lipoproteins on their surface that are crucial for the lipase-
mediated breakdown of TGs into their FA and glycerol components (12).  These FAs are 
then taken up by adipocytes for storage via FA transport proteins (FATPs), while the 
chylomicron remnants re-enter the blood stream.  In the postprandial state, these FAs are 
transported into the liver, elongated and esterified into TGs within the LD of the 
hepatocyte cytoplasm.  In fasted conditions they are rapidly metabolized via β-oxidation 
to provide energy (12).  This oxidation occurs within the mitochondria, peroxisomes and 
endoplasmic reticulum (ER) and is required to generate electrons to drive ATP synthesis 
by the electron transport chain (12).  β-oxidation, however, is inhibited in the fed state 
and DNL is promoted, thus allowing for lipid storage and distribution.  This hepatic lipid 
storage may arise from two major routes: the uptake of circulating FAs by hepatocytes as 
described above or via DNL from non-lipid precursors including dietary carbohydrates 
(i.e., glucose) (121).  Once FAs are esterified into TGs they can either be stored within 
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the hepatocyte LD or they can be secreted as TG-enriched lipoproteins (VLDLs) into 
circulation (57).  
The results herein are highly dependent upon the understanding of hepatic 
lipogenesis, which includes the de novo synthesis of FAs by glycolytic conversion of 
glucose to acetyl-CoA and malonyl-CoA, and further elongation and esterification of FAs 
to generate hepatic TGs (111).  Lipogenesis is both insulin and glucose-dependent and 
under strict transcriptional control by SREBP-1c and carbohydrate response element 
binding protein (ChREBP).  These transcription factors are activated by insulin and 
carbohydrates, respectively, eliciting changes in the expression of lipogenic genes that 
catalyze the rate limiting steps of FA synthesis; acetyl-CoA carboxylase (Acc) and fatty 
acid synthase (Fasn) (84, 111).  Although originally discovered as a transcription factor 
involved in cholesterol biosynthesis, SREBP-1c is a major mediator of insulin action on 
GK and many other lipogenic genes including ATP citrate lyase (Acyl), ELOVL family 
member fatty acid elongase 6 (Elovl6), glycerol-3-phosphate acyltransferase (Gpat), 
diacylglycerol acyltransferase (Dgat), and stearoyl-coenzyme A desaturase 1 (Scd1) by 
binding to the sterol regulatory element (SRE) present in the promoters of these genes 
(33, 35).  Transgenic over-expression of hepatic SREBP-1c in mice increases hepatic TG 
accumulation (steatosis) and increased mRNA expression of most lipogenic genes (213).  
Consistent with this, SREBP-1c KO mice have impaired lipogenic gene expression after 
high carbohydrate feeding, which is known to rapidly induce hepatic Fas mRNA 
expression (35, 131).  Additionally, SREBP-1c is elevated in the livers of IR rodents, 
suggesting its involvement in the pathogenesis of hepatic IR (35).  Taken together, these 
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results indicate that hepatic carbohydrate and lipid metabolism are intimately connected 
and dysregulation of one or more of these pathways will perturb metabolic control and 
ultimately lead to IR and T2DM.   
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Figure 1.5. Mechanisms contributing to hepatic lipid accumulation. In the context of 
obesity, a disruption of 1 or more of the pathways of hepatic lipid metabolism contribute 
to hepatic fat accumulation.  (1) Increased delivery of FFAs as the result of over nutrition 
and the increased release of FFAs from AT as a result of increased lipolysis. (2) 
Decreased hepatic FFA oxidation. (3) Increased hepatic de novo lipogenesis caused by 
hyperinsulinemia, hyperglycemia and increased FFA delivery. (4) Decreased export of 
TG-rich lipoproteins in the form of VLDL secretion into circulation. 
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1.7.3. Hepatic Steatosis and NAFLD 
NAFLD represents the most prevalent liver disease in Westernized countries.  
NAFLD is the hepatic manifestation of the MS and IR, and it frequently occurs as part of 
the metabolic changes that accompany obesity, T2DM and dyslipidemia (4). In obese 
humans, steatosis prevalence is approximately 75% and nearly 35% of these individuals 
progress to developing NASH, a condition that occurs when steatosis is accompanied by 
inflammation (2).  NASH can further progress to fibrosis with an increased risk to 
develop end-stage liver disease or hepatocellular carcinoma (12).   
Hepatic steatosis is characterized by intracellular TG accumulation and the 
subsequent formation of LDs in hepatocytes causing liver enlargement.  Hepatic steatosis 
in the context of obesity and IR occurs when there is an imbalance in hepatic lipid 
metabolism (summarized in Figure 1.4.):  (1) An excess supply of FAs coming from 
dietary intake or increased lipolysis from obese AT, (2) decreased FA β-oxidation, (3) 
increased DNL and (4) decreased VLDL export.  Quantitative analysis using labeled 
isotopes in patients with NAFLD revealed that 59% of the labeled hepatic TGs were 
derived from circulating FAs from increased AT lipolysis, 26% were from hepatic DNL 
and 15% were from the dietary sources (46).  Isotope tracing of VLDL in normal subjects 
versus obese subjects reveals a significant increase in export from 2-5% to 25-30%, 
indicating that NAFLD patients may have impaired export and thus display hepatic TG 
accumulation (42, 46).  
Although TGs are relatively inert, intracellular FA accumulation within 
hepatocytes and KCs can activate resident immune cells within the liver causing the 
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progression of steatosis to NASH.  This progression is inevitably linked to the paracrine 
effect of increased pro-inflammatory cytokine secretion including TNF-α and IL-1β from 
AT and KCs within the liver, thus upregulating inflammatory signaling, oxidative stress, 
imbalanced circulating insulin-sensitizing adipokine levels and mitochondrial defects 
leading to decreased FA oxidation and hepatic lipotoxicity (2, 5, 12).  These cytokines 
derived from activated KCs exacerbate liver inflammation and increase hepatic lipid 
synthesis and TG accumulation (53, 76, 129).  Because of the significant association of 
NAFLD with obesity and IR, a common treatment for these patients is lifestyle 
intervention by the prescription of exercise and nutritional programs to achieve diet- or 
surgically-induced weight loss.  Diet-induced weight loss and laparoscopic adjustable 
gastric banding improve liver histology, however, the characteristic inflammation of 
NASH may be exacerbated by bariatric surgical techniques because malabsorption and 
gut diversion confound the effects of weight loss (3, 43).  TZDs also improve liver 
function by histologically decreasing necrosis, serum ALT, and improving fasting 
insulin, glucose and HOMA IR in NAFLD patients (20, 158).  Recently, anti-cytokine 
therapy has been utilized to treat alcoholic liver disease (ALD), the onset of which is 
caused by excess alcohol consumption.  Results in mice indicate that that 
pharmacological inhibition of IL-1 signaling by recombinant interleukin-1 receptor 
antagonist (IL-1Ra) treatment had protective effects in various stages of ALD, including 
development and progression of steatosis to steatohepatitis and fibrosis (181).  Chapter 3 
of this dissertation demonstrates that IL-1Ra administration in DIO mice to attenuate 
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hepatic steatosis, illustrating a therapeutic approach to NALFD treatment in the context 
of IR and obesity.   
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1.8. Inflammation and Metabolic Disease   
The association between inflammation and metabolic disease was discovered well 
over 100 years ago in studies using anti-inflammatory agents to normalize glycemia.  The 
earliest reports in presumed T2DM and IR patients noted decreased glycosuria, or 
glucose in the urine, after treatment with high doses of sodium salicylate, the primary 
metabolite of aspirin (11, 215, 258).  A resurgence regarding the effects of salicylates 
occurred 50 years later when a T1DM patient no longer required daily insulin injections 
after being given high-dose aspirin to treat the arthritis that was associated with 
rheumatic fever (11).  However, when additional patients were treated with salicylates, it 
was recognized that maintenance of normoglycemia required continuous high-dose 
treatment and these patients suffered from salicylate toxicity (11).  These data 
demonstrate the importance in our understanding of the mechanistic link between 
inflammation and systemic glucose regulation.  
Case studies conducted in IR and non-disease control subjects revealed increased 
secretion of inflammatory mediators (TNF-α, IL-1β, IL-6) and circulating acute phase 
proteins including C-reactive protein (CRP) and serum amyloid A (SAA) in IR patients 
(195, 222).  Additional increases in serum levels of IL-1Ra, an anti-inflammatory acute 
phase protein, are also observed in obesity-induced IR patients (66, 103).  Surgically 
induced weight loss by gastric bypass reduces circulating IL-1Ra levels, thus illustrating 
the immune effects induced by obesity (145).  However, it was the discovery in 1971 by 
Vane and colleagues, who were awarded the Nobel Prize, that revealed the anti-
inflammatory effects of aspirin is via the inhibition of prostaglandin synthesis, and 
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further research has found the effects to be partially mediated by nuclear factor kappa b 
(NF-kB) inhibition (described in section 1.10.2.) (117, 240).  More recently it was 
discovered that salicylates mediate their effects on insulin sensitivity by inhibiting the 
inhibitor of kappaB kinase β (IKKβ) to improve hyperglycemia, hyperinsulinemia, and 
dyslipidemia in obese rodents (264, 266).  Although the role of immune activation in IR 
and T2DM progression remains incompletely defined, the emerging study of 
immunometabolism has enhanced our understanding of the mediators and signaling 
mechanisms involved (56).      
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1.9. The Immune Response in Adipose Tissue 
The endocrine and metabolic functions of AT and the subsequent changes in 
systemic physiology are intimately controlled by changes in insulin sensitizing and 
inflammatory adipokine secretion.  In recent years, much effort has been devoted to 
understanding the immune response that ensues in AT in obesity.  Though many 
hypotheses have been brought forth to explain why this immune response occurs, it is 
clear that the metabolic complications along with increased immune cell infiltration and 
secretion of pro-inflammatory cytokines are directly related the chronic state of low-
grade inflammation within the AT of obese humans and mice.  This is determined by the 
increased expression of pro-inflammatory mediators TNF-α, IL-6, IL-1β, iNOS, CRP, 
MCP-1 and others (62, 245, 252).  Adipocytes express the receptors for several of these 
cytokines supporting the hypothesis that adipocytes are both the source and the target of 
these pro-inflammatory signals (252).  However, data suggests that in AT, the pro-
inflammatory molecules including IL-1β, PG-E2, TNF-α, and IL-6, are primarily 
produced by the growing stromal vascular cell population (SVC) (198, 252).  The SVC 
fraction is comprised of pre-adipocytes, fibroblasts, mast, endothelial and immune cells; 
the most abundant and well-studied of these cells are adipose tissue macrophages 
(ATMs).  The inflammatory processes by these ATMs are also mimicked by KCs, or 
resident liver macrophages that drive the obesity-induced hepatic inflammatory response 
secondary to AT inflammation.   
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1.9.1. Hypotheses of Adipose Tissue Inflammation 
The homeostatic program of AT is maintained in a complex manner through the 
paracrine and autocrine interactions of adipocytes, endothelial cells, immune cells, and 
others.  Changes within the expanding AT perturb this local environment and elicit 
microenvironmetal cues and signals to other cells, thus evoking a chronic immune 
response.  Recent studies suggest that this immune response in obese AT is causal to the 
increased basal lipolysis and circulating lipids that are associated with obesity and IR 
(discussed in section 10.1.1) (118).  Disruptions in the vascularization of expanding AT 
cause local hypoxia, which is also suggested to cause the dysregulation of adipokine 
secretion, pro-inflammatory macrophage recruitment and local AT inflammation in 
obesity (48, 90).  Another hypothesis of AT inflammation identifies that hypertrophic 
adipocyte necrosis is an important modulator of macrophage responses by the appearance 
of crown like structures (CLS) surrounding dying adipocytes in expanding AT (30).  
Importantly, attenuation of this immune response and subsequent inflammation improves 
IR and it is without question that ATMs are the primary source of this local AT 
inflammation in obesity (9, 216, 220, 237, 252).  However, the complete immune 
program and involvement of other immune cell types remains incompletely defined. 
 
1.9.2. Immune Cells in Adipose Tissue 
 The metabolic state of AT modulates both the quantities and proportions of 
immune cells as illustrated by the increasing shift in immune cell populations with 
increasing adiposity (55, 252).  Of the immune cells, ATMs represent the largest and 
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most well-studied within obese AT and are the primary source of inflammatory 
cytokines.  Immune cells, however, are not selective to obese AT; macrophages, mast 
cells and T and B lymphocytes also accumulate in the AT depots of lipodystrophic mice 
confirming their contribution to inflammation and IR (88).  ATMs are discussed 
extensively in the following sections and throughout chapter 2 and therefore this section 
will be devoted to the analysis of other immune cells and their contribution to local AT 
inflammation.   
Recent studies suggest that included in the first wave of cells to respond to acute 
infection or tissue injury are neutrophils, which are mononuclear cells that facilitate the 
recruitment of macrophages, dendritic cells and lymphocytes, thus initiating the immune 
response (55).  A recent study demonstrated that short term HFD in mice causes a 
significant recruitment of neutrophils to the VAT, peaking at 3-7 days and preceding 
macrophage accumulation in AT (47).  It has also been demonstrated that β3-adrenergic 
stimulation by catecholamines in vivo, used to mimic the increased AT lipolysis in 
obesity, causes rapid infiltration of neutrophils into AT depots of mice, specifically VAT 
(199).  In contrast, the elevation of inflammatory gene expression and macrophage 
infiltration are significant in AT after 3 days of HFD, although to a lesser extent than 
induced by chronic feeding (128).  Thus, the immune cells responsible for initiating local 
AT inflammation still remains elusive and contributing cell types continue to be 
accounted for. 
While the immune response responsible for AT inflammation is causal to the IR 
in obesity, not all immune cells within the AT cause inflammation.  Studies have reported 
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the presence of anti-inflammatory cytokines within AT, including interleukin 4 (IL-4), 
interleukin 10 (IL-10), interleukin 13 (IL-13) and transforming growth factor β (TGF-β) 
(63, 136).  In lean mice, eosinophils are a large portion of the SVCs and inversely 
correlate with increasing adiposity (260).  Identified by the expression of surface marker 
sialic acid–binding immunoglobulin receptor (SiglecF), eosinophils can modulate 
macrophage activation to an anti-inflammatory state (M2) with insulin sensitizing affects 
in AT by IL-4 secretion (260).  The remaining SVCs in lean mice are made up of 
lymphocytes including CD4+ and CD8+ T cells, innate helper type cells (TH), invariant 
natural killer T cells (iNKT), B cells and others.   
Regulatory T cells (Tregs) promote the anti-inflammatory activities of cells of the 
innate immune system including TH cells and macrophages (115).  Tregs are CD4
+ and 
decrease with obesity like eosinophils, but Tregs are only a subset of CD4
+ lymphocytes 
found in AT (58).  Other CD4+ and CD8+ T cells increase in parallel with increasing 
adiposity including CD4+ TH1 cells that promote inflammatory cues by secreting 
interferon γ (IFNγ) (115, 259).  Interestingly, CD8+ T cells have recently been 
demonstrated to play a role IR pathogenesis because genetic depletion of CD8+ T cells 
reduces macrophage infiltration into the AT of obese mice and ameliorates systemic IR 
(162).  Like neutrophils, these CD8+ T cells precede macrophage accumulation into the 
AT of mice challenged by HFD and are necessary for AT inflammation (162).  
Additionally, genetic deletion of iNKT cells ameliorates the development of AT 
inflammation and glucose intolerance in DIO, however, studies evaluating the number of 
these cells in obese AT are conflicting (23, 172).  Furthermore, a small population of 
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lymphocytes (B cells) is present within the AT, and much like T cells are divided into 
distinct B cell populations.  B cells secrete antibodies to assist in the destruction of 
pathogens by phagocytes including macrophages, however, a distinct subset of Bregs 
inhabit the AT and secrete IL-10 to restrain AT inflammation and maintain metabolic 
homeostasis in DIO mice (163).  Lastly, the inflammatory mast cell is increased in the 
AT from obese subjects compared with that from lean donors and their deficiency 
improves glucose tolerance and insulin sensitivity in obese mice (132).  Taken together, 
these data suggest that many subtypes of immune cells are responsible for AT 
inflammation and are required to control both the macrophage content and polarization 
state within obese AT. 
 
1.9.3. Adipose Tissue Macrophages 
Obesity-induced AT inflammation is primarily mediated by both innate and 
adaptive immune cells residing in the SVC fraction as described above.  Characterization 
of these cells by Weisberg and colleagues piloted the emergence of immunometabolism 
with evidence that macrophage activation within AT drives the obesity-related immune 
response and IR (252).  Because adiposity does not predict IR, studies in our laboratory 
combining expression profiling with computational approaches determined that elevated 
inflammatory gene expression can distinguish the omental AT of IR obese patients from 
that of IS obese individuals, even though they are matched for body mass index (BMI) 
(82).  When analyzed by fluorescence activated cell sorting (FACs), ATMs within 
omental and VAT of obese humans and mice increase in parallel with increasing 
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adiposity (252).  In agreement, approximately 5% of cells in the lean AT are F4/80+ 
macrophages (described below), whereas this number increases to approximately 40% of 
cells in obese individuals and to upwards of 50% in obese mice illustrating a drastic shift 
in macrophage proportions within AT (252).  In agreement, histological analysis of 
omental AT from obese IS and IR patients determined that increased adipocyte size and 
macrophage infiltration into AT is a better predictor of IR than clinical measures of 
adiposity; highlighting the significance of understanding macrophage populations within 
obese AT, specifically the VAT/omental depot (82).  
Macrophages are identified by the characteristic expression of surface markers 
F4/80 (EMR1), CD68 and CD11b (Itgam), and represent the most functionally and 
numerically dominant immune cell (leukocyte) in the SVC fraction.  Encompassed within 
F4/80+ macrophages are a heterogeneous hematopoietic cell population with different 
immunophenotypes based on surface marker protein expression.  Sorting cells with 
specific surface marker combinations using flow cytometry has provided mechanistic 
details on the functional role of macrophages within AT and how their activation 
contributes to obesity-induced IR.  Importantly, ATMs in lean mice are phenotypically 
distinct from those in obese mice by exhibiting different inflammatory potentials and are 
classified in an activation spectrum of polarization states.   
There is a dichotomous, yet simplistic classification of ATMs categorizing them 
as anti-inflammatory alternatively activated (M2) macrophages, which express specific 
genes including Arginase 1 (Arg1), CD206 (Mrc1) and CD301 (Mgl1).  These resident 
ATMs secrete anti-inflammatory cytokines IL-4 and IL-13, which are essential to the 
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homeostatic functions of AT including tissue repair and remodeling (167).  In contrast, 
ATMs in a classical pro-inflammatory (M1) activation state express CD11c (Itgax) and 
can drive inflammatory signaling cascades by releasing TNF-α, IL-1β and MCP-1.  
Resident ATMs of lean mice are not CD11c+, but a phenotypic switch occurs with 
increasing adiposity connecting the M1 macrophage to obese AT (136).  In addition to 
infiltration, in situ proliferation driven by MCP-1 is an important process by which 
macrophages accumulate in obese VAT (1).  It is important to note that CD11c+ ATMs 
correlate with IR in obesity (167-168).  A more comprehensive subdivision of 
macrophage activation exists and illustrates the plasticity, versatility and antigenic 
diversity of ATMs.  For the extent and purposes of discussing the projects herein, the 
concept that ATM content is closely correlated with IR is most important.  Therefore, we 
sought to investigate the inflammatory potential of ATMs within the AT by combining a 
computational approach and gene expression profiling in hypertrophic, IR DIO mouse 
AT.  These results are described in Chapter 2. 
Recently, much effort has been taken to alter AT macrophage content to 
determine whether AT macrophage content can in fact alter IS in obese mice and 
humans.  Lifestyle and/or surgical intervention to induce substantial weight loss in obese 
subjects both decrease ATM content and inflammatory gene expression (16, 21).  The use 
of insulin sensitizing TZDs, specifically rosiglitazone, in genetically obese ob/ob mice 
yields significant reductions in macrophage marker gene expression in AT (261).  These 
methods demonstrate a correlation of reduced ATM content with improved systemic IS.  
In agreement, recent studies using conditional macrophage ablation techniques have 
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obtained similar results.  One such method is based on transgenic diphtheria toxin 
receptor (DTR) expression under the control of the CD11c promoter to conditionally and 
globally ablate CD11c+ cells.  A marked reduction in CD11c+ macrophages in AT along 
with local and systemic decreases in pro-inflammatory cytokines and a normalization of 
IS was observed in DTR-BM DIO mice (179).  Additionally, selective macrophage 
depletion in vivo can be executed using the liposome-mediated intracellular delivery of 
dichloromethylene-bisphosphonate (clodronate) (239).  This method selectively targets 
phagocytes by inducing apoptosis as intracellular clodronate concentrations increase.  
The success of this method is dependent upon the concentration of clodronate 
incorporated into the liposome preparation, timeline and injection strategy.  Feng and 
colleagues report that intraperitoneal (i.p.) clodronate liposomes injection in DIO mice 
markedly reduces ATM and KC content, improves systemic glucose tolerance and IS, 
and alleviates obesity-induced steatosis (54).  Conversely, Clemente, et al reported 
significant increases in VATM content in DIO mice treated with clodronate liposomes 
i.p. demonstrating inconsistencies in the literature using this method.  We sought to 
investigate these inconsistencies using clodronate in 2 models of mouse obesity and the 
results are discussed in Chapter 3.  In contrast to depleting macrophages, investigators 
have also used transgenic approaches to drive macrophage accumulation by 
overexpressing MCP-1 in AT. These studies report robust increases in macrophage 
content in both lean and obese mice accompanied by decreased IS (107-108).  Taken 
together, these studies highlight the importance in studying the molecular mechanisms 
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whereby macrophage-induced inflammatory processes contribute to systemic IR and 
inflammation.  
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1.10. Inflammatory Pathways and Insulin Resistance 
Inflammation causes IR via a number of molecular mechanisms, and the affects of 
pro-inflammatory cytokines on insulin signaling in peripheral insulin-sensitive and 
producing tissues is profound.  One mechanism whereby inflammatory signaling causes 
IR is via the inhibitory phosphorylation of serine residues on IRS-1 by stimuli such as 
TNF-α or FFAs (253).  This phosphorylation reduces both insulin-stimulated IRS-1 
tyrosine phosphorylation and the ability of IRS-1 to associate with the insulin receptor 
and thereby inhibits insulin action by preventing downstream signaling (180, 253).  
Inflammatory signaling pathways contributing to IR can also become activated by 
intracellular stress responses. The functional capacity of the ER is overwhelmed in 
obesity, which causes an ER stress response and consequent activation of inflammatory 
signaling pathways (176).  Additionally, increased glucose metabolism in obesity drives 
production of reactive oxygen species (ROS) by the mitochondria, which is also 
responsible for activating inflammatory signaling cascades (64).  Although these different 
areas of research provide mechanistic links between inflammation and IR, these findings 
have funneled into few primary signaling mechanisms responsible for inhibiting insulin 
action.  These pathways are described below and are illustrated in Figure 1.6. 
 
1.10.1. Cytokines and Insulin Resistance 
The work of Gohkan Hotamisligil and Bruce Spiegelman discovered that TNF-  
was overexpressed in obese rodents and humans gave insight to the mechanistic links 
between obesity and inflammation (56, 237).  TNF-α is a pleiotropic cytokine that has a 
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beneficial involvement in wound healing and pathological mediation of cellular apoptosis 
and inflammation (85, 263).  TNF-α promotes cellular inflammatory responses by tumor 
necrosis factor receptor 1 and 2 (TNFRI and TNFRII) activation (85).  This causes 
recruitment of several intracellular adaptor proteins to activate multiple signal 
transduction pathways to alter gene expression through nuclear factor kappa B (NFκB) 
and activator protein-1 (AP-1) signaling.  These pathways upregulate cytokine 
expression, and negatively regulate insulin receptor signaling by increasing serine 
phosphorylation of IRS-1, which directly interferes with insulin signaling (85, 93, 138, 
160, 233).  TNF-α also downregulates adiponectin secreted by adipocytes that sensitizes 
liver and muscle to insulin in rodents and humans, therefore decreasing insulin sensitivity 
(160).  As described above, increased TNF-α expression also induces chronic lipolysis, 
which increases serum FFA levels and promotes ectopic lipid deposition and IR in 
muscle and liver (221).  TNF-α also opposes the beneficial functions of PPARγ by 
inducing a rapid and potent reduction in adipocyte and macrophage PPARγ expression 
(168).  These data were confirmed by the generation of TNF-α or TNF-α receptor KO 
mice, which displayed protection against DIO and IR (237, 241).  TNF-α neutralization 
in obese rats also lowered plasma glucose and lipid levels, thus improving insulin 
sensitivity and providing the first evidence that inflammatory mediators can cause IR 
(92).  However, this improved insulin sensitivity was not observed in obese, IR patients 
following recombinant TNF-α antagonist administration (178).  Although TNF-α 
antagonists were not successful clinically, it remains important to understand the 
signaling mechanism(s) that require the action of TNF-α and other cytokines.   
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Investigators have since identified many other cytokines that modulate insulin 
action, and one such family of cytokines and a particular focus of this dissertation is the 
IL-1 family, which includes both the pro-inflammatory and anti-inflammatory, IL-1β and 
IL-1Ra, respectively.  Blockading IL-1-induced inflammation in humans by 
administration of recombinant IL-1Ra or IL-1β antibodies has demonstrated a central role 
of IL-1β in a number of inflammatory diseases including rheumatoid and osteoarthritis 
and myeloma (40).  In obesity, IL-1β expression increases in the pancreas, AT and liver 
and it impairs insulin secretion and induces β-cell apoptosis (103, 125).  Similar to TNFα, 
IL-1β is produced by macrophages and correlates with IR (41, 122, 153).  Interestingly, 
IL-1Ra expression is reduced in T2DM patients and administration of recombinant IL-
1Ra in these patients improves glycemia and β-cell function and also reduces systemic 
inflammatory markers (CRP and IL-6) (125).  β-cell production of IL-1β is enhanced by 
diet-derived FAs and high glucose levels, implicating its involvement in the pathogenesis 
of diabetes (41).  IL-1β also decreases the ability of insulin to stimulate glucose transport 
in both human and mouse adipocytes (102).  Like TNF-α, IL-1β can promote its own 
transcription by signaling through the IL-1 receptor complex to target IKKβ and NFκB to 
drive gene transcription.  However, a caspase-dependent signaling mechanism is also 
required to promote its activation via the NLRP3 inflammasome; an innate immune 
response that involves the formation of a multiprotein caspase-1-activating complex 
containing cysteine-aspartate protease-1 (caspase-1), apoptosis-associated speck-like 
protein containing a CARD (ASC), and a Nod-like receptor (NOD) protein (NLRP) (39, 
44).  Formation of the inflammasome complex activates caspase-1, which proteolytically 
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cleaves the IL-1β precursor into the mature active form that is secreted (250).  HFD-
induced elevation of FAs activate the inflammasome, which result in IL-1β production 
and impaired glucose tolerance and insulin sensitivity (254).  These data pioneered the 
studies designed to understand how the molecular effects of obesity activate the immune 
system, and how activation of inflammatory signaling influences the progression of IR. 
 
1.10.2. Inflammatory Signaling Pathways in Insulin Resistance 
The expansion of AT in obesity and the subsequent increase in inflammatory 
cytokines promotes cellular inflammatory responses by activating canonical pathways 
that mediate inflammatory signaling; the stress kinase, c-junN-terminal activated kinases 
1 and 2 (JNK1/2), protein kinase C theta (PKCΘ) and the inhibitor of NFκB kinase IKK 
(89, 233, 266).  The activities of both JNK and IKKβ/NFκB are increased with increasing 
adiposity and genetic or chemical inhibition of these pathways improves IR providing a 
link to their involvement in metabolic disease (242, 266).  JNK and NFκB represent the 
most well studied and potent inflammatory signaling cascades in the context of regulating 
insulin signaling (38, 211, 268).  Cytokines can stimulate a feedback loop via these 
pathways whereby they can exacerbate and drive their own production, however, other 
initiators of inflammatory activation include lipid metabolites, FAs and cellular stress 
responses including endoplasmic reticulum (ER) and oxidative stress. (64, 176, 211, 
226).  These ligands can also activate the p38 stress-activated protein kinase (p38 SAPK), 
extracellular signal-related kinases 1 and 2 (ERK1/2), toll-like receptors (TLRs) and 
others, and they also recruit adaptor proteins and signaling molecules to activate mitogen 
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activated protein kinase (MAPK) signaling and IKKβ to coordinate inflammatory 
responses through activation of NFκB to activate inflammatory gene transcription and 
ultimately promote the same inflammatory processes (133, 157).  Once activated, the 
downstream consequences of these pathways include production of pro-inflammatory 
cytokines and cellular adhesion molecules that recruit and localize immune cells, 
including monocytes and macrophages to provoke the immune response (215).   
JNK is a central metabolic regulator in the development of obesity-induced IR 
(242).  In obesity, JNK activity is elevated in liver, muscle, and AT, and an absence of 
JNK1 results in decreased adiposity, improved insulin sensitivity and enhanced insulin 
receptor signaling in diet-induced and genetic mouse models of obesity (89, 242).  JNK-
mediated inhibitory phosphorylation of IRS1 may contribute to obesity-induced IR 
development, but IRS-independent mechanisms also play important roles as mediators 
of IR (200).  Suppression of the JNK pathway can protect β-cells from glucose toxicity 
(109).  Modulation of hepatic JNK1 by dominant negative over-expression in obese mice 
restores insulin sensitivity (155).  Interestingly, JNK1 deficiency in hematopoietic cells 
by adoptive transfer in obese mice has no effect on adiposity, but protects against diet-
induced IR by decreasing obesity-induced inflammation and macrophage accumulation in 
AT (219).  In agreement, deletion of both JNK1/2 in macrophages protects against 
obesity-induced IR, and these mice display reduced hepatic TG accumulation and 
inflammatory gene expression (80).  These data indicate that JNK signaling, specifically 
in macrophages, is required for both AT and liver macrophage accumulation and diet-
induced IR.   
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Recently, the role of FAs derived from fat-enriched diets have emerged as key 
participants in obesity-induced inflammation.  Intracellular lipid metabolites, specifically 
diacylglycerol (DAG), fatty acyl-CoAs and ceramide, play a large role in inhibiting 
insulin action by activating TLRs, IKK and PKC-θ (253).  Circulating FFAs suppress 
insulin action by activating JNK and IKKβ in AT, liver and skeletal muscle (34, 159).  
Moreover, palmitate, a major FFA that is released from adipocytes, increases macrophage 
TNF-α production, which further augments FFA release and inflammatory changes in the 
AT (159, 225).  This macrophage response is thought to be signaled through TLR4, 
which is highly expressed on the surface of macrophages and is blunted in the absence of 
TLR4 (34, 211).  Mice heterozygous for IKKβ are partially protected against IR induced 
by lipid-infusion and diet- or genetically-induced obesity (112, 266).  Importantly, as 
described above, inhibiting IKKβ in IR patients by high doses of aspirin improves insulin 
signaling (98).  In agreement with the macrophage specific JNK deletion, macrophage 
IKKβ deletion protects against diet-induced IR.  However, when IKKβ is conditionally 
deleted in the hepatocytes of IR mice, these mice develop IR in muscle and AT and 
remain insulin sensitive in the liver.  Lastly, a more specific approach using an in vivo 
siRNA delivery system to target ATMs by glucan encapsulated siRNA particles (GeRPs) 
has been developed by our laboratory.  Targeting inflammatory mediators TNF-α and 
osteopontin in VATMs of genetically obese mice by administration of GeRPs i.p. 
significantly improved systemic glucose tolerance (7).  Taken together, these data are 
consistent with the hypothesis that cytokines produced by macrophages, specifically 
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ATMs, can exacerbate whole-body glucose intolerance, thus providing evidence that 
macrophages are excellent therapeutic targets for obesity and T2DM treatment.    
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Figure 1.6.  Inflammatory pathways of insulin resistance.  Insulin action is transduced 
from the cell surface to cytoplasmic and nuclear responses via tyrosine phosphorylation 
of the insulin receptor substrates (IRS)-1/2.  However, the inhibitory serine residue 
phosphorylation on these same substrates by JNK1 and IKKβ, the central mediators of 
stress and inflammatory responses, potently inhibits insulin action, thereby directly 
linking these responses to insulin resistance.  In addition, the transcriptional activation of 
inflammatory genes by JNK1 and IKKβ induces insulin resistance in an autocrine and 
paracrine manner in insulin sensitive and insulin producing tissues.  Moreover, in obesity, 
the JNK1 and IKKβ signaling pathways are also activated by increased influx of free 
fatty acids and glucose as well as other intracellular stress responses.  Adapted from 
Chawla, et al. Annu Rev Pathol. 2011; 6: 275–297.  
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1.11. Specific Aims: 
Since the discovery that macrophages infiltrate the AT of obese mice and humans, 
investigators have taken a more functional approach to determine the role of these 
macrophages in obesity-induced IR.  The use of KO technology to remove mediators of 
systemic inflammation and alternative approaches to deplete macrophages has 
determined that macrophage-derived inflammation is pertinent to the development of IR; 
however, the causative connection remains in question.  It is well established by studies 
comparing lean and obese AT histology and genome profiles that macrophages infiltrate 
obese AT, become M1-polarized and localize to necrotic adipocytes to phagocytose cell 
debris (137, 252).  More recently, however, it was discovered that macrophages aid in the 
sequestration of FAs released from these dying cells and gives rise to foam cell formation 
within obese AT (118, 188, 252).  This accumulation of lipid species and the proliferation 
of lipid droplets in ATMs induces gene-expression networks associated with lipid 
metabolism in the macrophage and provides evidence of an alternative role of 
macrophages in obese AT (188).  Thus, the initial paradigm of macrophage-derived AT 
inflammation has evolved from the idea of macrophages solely causing inflammation to a 
more complex model in which ATMs might protect insulin sensitive tissues from 
lipotoxic events and subsequent immune cell activation.  In the midst of this paradigm 
shift regarding the purpose and activation state of macrophages in obese AT, we used 
whole-genome transcription profiling to delineate whether increased AT inflammation is 
because of increased macrophage activation or recruitment in obese mice.   
55 
 
Furthermore, the obesity- and inflammation-induced increases in VAT lipolysis 
cause increased delivery of FFAs to the liver causing hepatic lipid deposition and 
lipotoxicity, KC activation and hepatic IR.  Administration of recombinant IL-6, TNF-α 
or IL-1β can also cause acute hypertriglyceridemia by stimulating hepatic VLDL 
secretion and hepatic steatosis by stimulating hepatic DNL in obese mice (25, 28, 50, 52-
53, 76, 164).  To this end, it is essential in obesity-associated NAFLD treatment to 
understand the molecular events modulating hepatic lipid metabolism and IR, which are 
caused by both hepatic and systemic inflammation.  Recently, macrophage depletion 
strategies have been used to determine the role of KCs in the development and 
progression of steatosis from a benign state to full-blown inflammation and fibrosis.  One 
such strategy is the use of clodronate-encapsulated liposomes to study the effects of 
macrophage depletion on steatosis development and progression in obesity.  However, 
this literature has diverged with growing contradictory phenotypes and hypotheses.  
Thus, to clarify this issue and elucidate the mechanism by which KC-derived pro-
inflammatory cytokines regulate hepatic lipid metabolism in obesity, we targeted KCs in 
vivo by i.p. clodronate liposome administration in two animal models of obesity.  
Furthermore, pharmacological inhibition of IL-1 signaling was used to decifer the role of 
IL-1β in hepatic lipid metabolism modulation in DIO mice.  
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CHAPTER II:  The Complex Roles of Adipose Tissue Macrophages:  A Genomics 
Approach to Define the Inflammatory Signature of Obese Mouse Adipose Tissue 
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2.1. Abstract 
Obesity is characterized by an expansion of AT and a chronic state of low-grade 
inflammation (77, 86, 91, 94, 252, 267).  The gene expression profiles and functions of 
resident and recruited ATMs have been extensively studied, and established the concept  
that infiltrating ATMs are M1-polarized with upregulated inflammatory gene expression  
and localize around necrotic adipocytes to phagocytose cell debris (137, 252).   More 
recently, however, it was discovered that ATMs have the ability to take up and sequester 
FAs released from these dying cells, giving rise to foam cell formation and indicating an 
alternative, non-inflammatory function of macrophage populations in obese AT (118, 
188, 252).  Thus, the initial paradigm of macrophage-derived AT inflammation has 
evolved from the idea of macrophages solely causing inflammation to a more complex 
model in which ATMs might protect insulin sensitive tissues from lipotoxic events and 
subsequent immune cell activation.  Here we describe a genomics approach to determine 
whether ATMs in an obese animal model display inflammatory properties.  We used 
whole-genome transcription profiling to determine the changes in inflammatory gene 
expression relative to macrophage-specific gene expression in both lean and DIO mouse 
AT.  DIO mice displayed glucose intolerance and IR compared with lean control mice.  
AT inflammatory and macrophage-specific gene expression profiles were compared with 
microarray data that was performed on thioglycollate-elicited peritoneal macrophages 
(PECs) stimulated with lipopolysaccharide (LPS), which induces M1 polarization and 
cytokine release.  We determined that common macrophage markers (CD68, F4/80, 
CD11b, and CD11c) were not affected by LPS treatment of PECS and these genes were 
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therefore used as a measure of the macrophage content within the AT.  We determined 
that these markers were significantly increased as much as 35 fold in DIO mouse VAT, 
but not in SAT, consistent with an expansion of the macrophage population in VAT.  
Expression of inflammatory cytokines and chemokines (TNF-α, IL-1β, IL-6, and MCP-1) 
was also elevated in DIO mouse VAT and markedly elevated in LPS-activated control 
macrophages as expected, consistent with previous reports in which VAT inflammation 
was attributed to infiltration of M1 polarized macrophages.  However, relative to 
macrophage-specific standards like F4/80, the expression of these inflammatory markers 
is unchanged.  These data indicate that the changes in the overall inflammatory profile of 
DIO mouse VAT is because of quantitative changes in the ATM number and not 
qualitative changes in their activation state.  These observations are consistent with the 
idea that infiltrating ATMs may have roles other than the previously described role in 
mediating inflammation in obese AT. 
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2.2. Introduction 
Obesity and IR are associated with a complex immune program and chronic low-
grade inflammation in AT where resident and recruited macrophages and other immune 
cells play a significant role in systemic insulin sensitivity (77, 91, 252, 267).  Many 
hypotheses have been brought forth to explain why this immune response occurs 
including ER and oxidative stress, lipotoxicity and AT hypoxia (90, 176, 236).  It is clear, 
however, that the metabolic complications along with increased immune cell infiltration 
and secretion of pro-inflammatory cytokines are directly related the chronic state of low-
grade inflammation within the AT of obese humans and mice and potentiate IR (86, 91, 
252, 267).  Studies in our laboratory combining expression profiling with computational 
approaches discovered that the AT of IR obese patients exhibits higher expression of 
inflammatory genes than the AT of IS obese individuals matched for BMI (82).  
Additionally, when analyzed by flow cytometry, the omental AT of obese individuals 
demonstrates parallel increases in adiposity and macrophage accumulation. The 
significant accumulation of macrophages to become approximately 40% of cells within 
the AT illustrates a drastic shift in macrophage proportions in obesity (252).  In 
agreement with these data, histological analysis of omental AT from obese IS and IR 
patients determined that increased adipocyte size and macrophage infiltration into the AT 
is a better predictor of IR than clinical measures of adiposity, highlighting the 
significance of understanding macrophage populations within obese AT, specifically the 
omental depot (82).    
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It has been extensively reported that both macrophages and adipocytes express 
inflammatory mediators, including TNF-α, IL-6, IL-1β, iNOS, MCP-1 and others; 
however, ATMs have been identified as the key regulators of the inflammatory 
phenotype displayed by obese AT (63, 134, 188, 252).  ATMs are primarily increased in 
the omental AT depot of obese individuals and correlate with measures of obesity-
induced IR (83).  Although much effort has ensued to understand the recruitment or 
expansion of inflammatory macrophage populations within obese AT, resident tissue 
macrophages are also present within lean AT.  The properties and functions of both 
resident and recruited ATMs are determined by their polarization toward an 
inflammatory or anti-inflammatory activation state.  Macrophage polarization exists as a 
continuum characterized by specific gene expression profiles, but a simplistic 
differentiation between two activation phenotypes has been used to classify ATMs in 
obesity: classically activated (M1) or alternatively activated (M2) macrophages.  This 
dichotomous classification of ATMs as either M1 or M2 does not fully capture both the 
diversity and functions of ATMs, but simplifies the nomenclature for defining 
macrophage populations within obese AT. 
ATMs from lean individuals are predominately CD11c− and the first antigenically 
distinct subpopulation of ATMs to be discovered express the integrin CD11c (55).  
Although CD11c− and CD11c+ ATM populations increase in obesity, CD11c+ population 
expansion is much greater than CD11c− cells (55, 210).  Originally characterized as M1 
polarized, the CD11c+ ATMs are thought to contribute disproportionately to the 
inflammatory phenotype and metabolic dysfunction of obese AT because M1 
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macrophages have enhanced production of inflammatory cytokines TNF-α and IL-1β, 
known to contribute to obesity-induced IR (63, 93, 136, 222).  Functional studies in mice 
have demonstrated that ablation of CDllc+ macrophages and genetic deletion of 
molecules involved in inflammation (TNF-α, IKKβ, NLRP3, etc), results in improved 
glucose tolerance and insulin sensitivity, indicating their importance in metabolic disease 
pathogenesis (9, 237, 254).  On the other hand, M2 ATMs, which are the major resident 
macrophages in lean AT, are characterized by the expression of arginase 1 (Ym-1), 
CD206, macrophage galactose N-acetyl-galactosamine specific lectin 1 (Mgl1), and IL-
10, all known to be involved in tissue repair and remodeling (26, 63).  Several groups 
have reported that CD11c+ ATMs are negative for these M2 markers of alternative 
activation, however, this has not been consistently found in rodents and humans (55, 208, 
210, 255).  Interestingly, the impairment of alternative macrophage activation by 
macrophage-specific PPARγ deletion results in DIO, IR, and glucose intolerance, 
highlighting the importance of M2 macrophages in maintaining systemic insulin 
sensitivity (168).  Thus, ATM characterization is evolving away from the M1/M2 
paradigm and toward a general understanding of the purpose, presence, and function of 
expanding ATM populations in obese AT.  For simplicity, the macrophages referred to 
herein with be referenced as M1-like and M2-like to depict inflammatory or anti-
inflammatory populations.    
Evidence associating a phenotypic switch in ATM polarization from an anti-
inflammatory M2-like state toward a pro-inflammatory M1-like state exists in DIO 
mouse models (136).  The significance of this switch in polarization state is highlighted 
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by the random scattering of M2-like macrophages throughout the AT of lean mice versus 
the specific clustering of M1-like macrophages into CLS around necrotic adipocytes in 
obesity, demonstrating a change in ATM distribution that correlates with increasing 
adiposity (188, 252).  At the time of this study, it was of particular interest to understand 
whether the increased M1-like:M2-like ATM ratio in obese AT was because of 
transdifferentiation or the expansion of M1-like macrophages in obese AT, even though 
the standard model of AT inflammation proposes that macrophages infiltrate obese AT 
and act as a conduit to initiate and exacerbate AT inflammation.  Therefore, it was 
expected that macrophage infiltration into the AT would result in an increased 
inflammatory profile of DIO mouse AT.  It is also known that resident tissue M2-like 
macrophages are at the junction of innate immunity and are responsible for inflammation 
resolution (167).  Thus, we hypothesized that both resident and recruited ATMs may 
serve an alternative function and act in a non-inflammatory and perhaps protective role 
within the AT; a role that had not been reported at the initiation of this study.   
To address this question, we compared the gene expression profiles of ex vivo 
activated macrophages to the genome wide expression in VAT and SAT from DIO mice 
to determine whether ATMs displayed similar elevation of inflammatory markers.  We 
used this strategy to distinguish between two possible outcomes: increased activation or 
recruitment of M1 polarized macrophages should result in disproportionately higher 
expression of inflammatory markers (TNF-α, IL-6, IL-1β) compared to common 
macrophage markers like F4/80.  On the other hand, if recruitment or expansion of the 
macrophage population occurs without activation, we would expect proportionate 
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increases in both categories of markers. In fact we observe the latter: as expected, VAT 
(but not SAT) from DIO mice show increased expression of inflammatory markers, 
however, this increase is proportional to the increase in general macrophage markers. 
This contrasts with the ex vivo M1 polarization model in which inflammatory marker 
expression is massively increased while general macrophage markers are unchanged.  
These data suggest that the changes in the overall inflammatory profile of DIO mouse 
VAT is mainly because of quantitative changes in ATM number and not qualitative 
changes in activation state. This is consistent with the idea that the expanded population 
of ATMs may include cells with alternative, possibly beneficial functions in obese AT. 
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2.3. Results 
High fat feeding promotes macrophage accumulation into VAT but not SAT of DIO 
mice. 
In human obesity, body type and fat distribution play an important role in the 
maintenance of systemic insulin sensitivity.  The anatomical location of AT determines 
the inflammatory profile, with VAT being associated with a more adverse risk profile 
than SAT for the metabolic syndrome and T2DM (61).  A number of studies have 
demonstrated that macrophages infiltrate the omental and VAT of obese humans and 
mice and a phenotypic switch from M2 to M1 activation state occurs, thus correlating M1 
accumulation with the development of systemic IR (252, 261).  Therefore, we wanted to 
confirm published data regarding the inflammatory signature of two anatomically distinct 
AT depots, VAT and SAT, and analyze whole AT by microarray analysis to determine 
macrophage-specific and inflammatory gene expression.   
To assess the inflammatory changes within obese AT, WT mice were fed a high 
fat diet for 13 weeks. These DIO mice gained more weight than lean control mice 
beginning at 3 weeks and remained significantly more obese throughout the end of the 
study (Figure 2.1 A; 30.9 ± 0.75 vs. 42.08 ± 0.78 g; p ≤ 0.001).  At the end of 13 weeks, 
DIO mice were more glucose intolerant as demonstrated by elevated fasting blood 
glucose concentrations (Figure 2.1 B; p ≤ 0.02), elevated fasting insulin levels (Figure 
2.1 C; p < 0.02), and increased area under the curve for the IPGTT (Figure 2.1. B; 
(min*mg/dL) = 29352 ± 753 vs. 38983 ± 1928; p ≤ 0.01).   
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Figure 2.1. HFD mice displayed glucose intolerance and insulin resistance at the end 
of 13 weeks.  WT mice were fed a ND or HFD for 13 weeks and glucose tolerance and 
insulin resistance were assessed by GTT.  A.)  Growth curves of C57BL6/J mice on ND 
(n = 12, dashed line) and HFD (n = 12, solid line).  Weights were significantly different 
at all time points after 3 weeks (* p < 0.001).  B.)  IPGTT of ND (n = 12, dashed) and 
HFD (n = 12, solid line) at 13 weeks (AUC with baseline correction = 29352 ± 753 vs. 
38983 ± 1928 (min*mg/dL); p ≤ 0.01).  C.) Fasting insulin levels of ND (n = 12, white) 
and HFD mice (n = 12, black) at 13 weeks (inside B. graph) (* p < 0.02).  The values are 
represented as the mean ± SEM.  An unpaired student’s t-test was used for comparisons 
between groups.  Figure from Fitzgibbons, et al. Am J Physiol Heart Circ Physiol. 2011.
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We used gene expression profiling of macrophage-specific gene expression to 
examine macrophage presence within the tissue as well as the inflammatory profile of the 
AT of DIO mice.  Our gene profiling experiment directly compared whole VAT and SAT 
explants to ex vivo activated peritoneal exudate cell macrophages (PECs) that were 
untreated or LPS-stimulated, which would drive an M1 gene expression profile to 
represent a classical M1-type macrophage as a control.  Upon LPS stimulation, 
macrophage-specific marker gene expression (F4/80, CD68, CD11c, CD11b) was 
unchanged (Figure 2.2 A) and therefore, these genes served as standard macrophage 
markers to determine the presence of macrophages within the AT.  Expression profiling 
was performed on total RNA preparations from whole AT, including adipocytes and the 
SVF which contains preadipocytes, fibroblasts, endothelial and immune cells.  Our data 
is consistent with previous observations as we observed mRNAs of these standard 
macrophage-specific markers to be significantly increased by as much as 8-fold in the 
VAT of DIO mice compared with lean control mice (Figure 2.2. A; p ≤ 0.01).  
Interestingly, we did not observe this increase in SAT (Figure 2.2. A).  Confirmation of 
the microarray by qRT-PCR illustrated that macrophage-specific marker gene expression 
was significantly increased 8-35 fold in the VAT from DIO mice compared with lean 
control mice (Figure 2.2. B; p ≤ 0.001).  No changes in macrophage marker genes are 
observed in the SAT of DIO mice compared with lean control animals (Figure 2.2 C).  In 
agreement with the genomics and qRT-PCR data, an enrichment of F4/80+ macrophages 
was observed by histology in the VAT but not the SAT of DIO or the AT of lean control 
mice (Figure 2.3 A-D).  These data illustrate that obesity drives increased macrophage 
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population into DIO mouse VAT without changes to the macrophage content in the SAT 
depot.  This indicates that the SAT and VAT depots respond differently to high fat 
feeding and suggests a potential different microenvironment within the two AT depots. 
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Figure 2.2.  Standard macrophage marker genes were unaffected by LPS treatment 
but are significantly increased in obese VAT and unchanged in SAT. Thioglycollate-
elicited PECs were isolated from 10-week old WT mice and stimulated ex vivo with LPS 
for 6 hours.  WT mice were HFD-challenged for 13 weeks and whole VAT and SAT was 
harvested from ND and HFD fed mice.  RNA was extracted from PECs and whole AT 
and microarray analysis was performed. The data are representative of 12 DIO, 12 lean 
mice and 3 experimental replicates ex vivo.   A) The data represent the average fold 
change of macrophage-specific surface marker mRNAs, which were not affected after 
LPS treatment in PECs (white bars) or the presence of these genes in VAT (grey bars) 
and SAT (black bars) of obese mice compared with lean controls. RNA was subjected to 
quantitative RT-PCR for macrophage-specific gene expression (CD68, F4/80, CD11b, 
and CD11c) to confirm the microarray data in B.) VAT and C.) SAT.  The values 
represent the mean ± SEM. An unpaired student’s t-test was used for comparisons 
between groups.  * p < 0.01, ** p < 0.001.   
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Figure 2.3.  SAT is resistant to diet-induced inflammation, but VAT is enriched with 
F4/80 positive macrophages in DIO mice.  C57Bl6/J mice were HFD-challenged for 13 
weeks and whole VAT and SAT was harvested from ND and HFD fed mice (n = 3 per 
group).  Samples were fixed in 4% formalin, sectioned, and stained with rat anti-mouse 
F4/80 primary antibodies (ABd Serotec).  Staining was visualized with HRP-linked rabbit 
anti-rat secondary antibodies.  Minimal staining was observed in the A.) SAT of lean 
control mice B.) SAT of DIO mice or in the C.) VAT of lean control mice.  Abundant 
macrophages were seen predominantly in the D.) VAT of DIO mice, forming crown like 
structures surrounding adipocytes.  Figure from Fitzgibbons, et al. Am J Physiol Heart 
Circ Physiol. 2011. 
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Markers of  inflammation show minimal or no change in obese VAT relative to 
macrophage-specific genes. 
ATMs produce pro-inflammatory cytokines and chemokines such as TNFα, IL-6 
and MCP-1/CCL2, which may contribute to the induction of IR (173).  The production of 
these canonical markers of inflammation increase in whole AT from obese mice, which is 
attributed to the presence of classically activated M1 macrophages (26, 262).  Because 
we observed significant increases in macrophage-specific marker genes in the DIO 
mouse VAT (Figure 2.2 A-B), we expected to find parallel increases in the mRNAs of 
classical gene products of inflammation.  These genes were markedly elevated, upwards 
of 60 fold in LPS-stimulated macrophages, an ex vivo model of macrophage activation 
(Figure 2.4 A; p < 0.001).  Though common macrophage markers are increased in VAT, 
the expression levels of inflammatory cytokine microarray data (TNFα, IL-1β, IL-6) are 
unchanged in the DIO mouse SAT or VAT when compared with lean control mice; 
inconsistent with the current belief that macrophages exacerbate inflammation within the 
AT of obese mice (Figure 2.4 A-B).  However, as expected, chemoattractant proteins 
MCP-1/CCL2 and MIP-1β/CCL4 were both significantly increased in DIO mouse VAT, 
with the latter also significantly increased in SAT (Figure 2.4 A; p ≤ 0.05).  These data 
encouraged the question of whether macrophages in obese mouse AT are in a classical 
M1 activation state.  Increased activation or recruitment of M1 polarized macrophages 
should result in disproportionately higher expression of inflammatory markers (TNF-α, 
IL-6, IL-1β) compared to common M1/M2 markers like F4/80.  However, we observed 
no elevation in the inflammatory signature of the DIO mouse AT compared with lean 
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control mice (Figure 2.5).  This suggests that the recruitment or expansion of the 
macrophage population in obese mouse VAT occurs without activation because the 
inflammatory gene expressions obtained from the microarray are unreflective of the 
enriched macrophage content.   
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Figure 2.4.  Genomic profiling of inflammatory markers in obese AT reveals 
minimal or no change in expression compared to M1-activated macrophages.  
Thioglycollate elicited PECs were isolated from 10-week old WT mice and stimulated ex 
vivo with LPS for 6 hours.  VAT and SAT was harvested from 13-week HFD-challenged 
WT mice.  RNA was extracted from PECs and whole AT of ND and HFD fed mice and 
microarray analysis was performed.  The data are representative of 12 DIO, 12 lean mice 
and 3 experimental replicates ex vivo.  The data represents the average fold change of 
classical inflammatory gene mRNAs.  LPS-treatment in PECs (white bars) significantly 
upregulates inflammatory gene expression indicating M1 polarization and activation of 
classical inflammatory signaling.  These genes demonstrate little or no significance in 
VAT (grey bars) or SAT (black bars) of DIO mice compared with lean control mice.  The 
values represent the mean ± SEM. An unpaired student’s t-test was used for comparisons 
between groups. * p ≤ 0.05, *** p ≤ 0.005. 
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Figure 2.5. Genomic profiling of inflammatory markers show minimal or no 
increase in obese VAT despite macrophage-specific gene enrichment.  VAT and SAT 
was isolated from 13-week HFD-challenged mice.  RNA was extracted from the whole 
AT of ND and HFD fed mice and microarray analysis was performed.  The data are 
representative of 12 DIO and 12 lean mice.  Macrophage-specific marker genes (CD68, 
F4/80, CD11b, and CD11c) are compared with mRNAs of inflammatory genes in VAT 
(grey bars) and SAT (black bars) to illustrate the blunted immune response in AT albeit 
macrophage-specific genes are enriched in VAT.  The values represent the mean ± SEM. 
An unpaired student’s t-test was used for comparisons between groups.  * p ≤ 0.05.  
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DIO mouse VAT inflammatory gene expression is proportional to the increase in 
macrophage-specific markers. 
We used a quantitative approach to clarify genomics data revealing a blunted 
immune response in the AT, particularly in the DIO mouse VAT.  Classical RT-PCR 
analysis is dependent upon the normalization of each gene of interest to a ubiquitously 
expressed, invariant endogenous control or housekeeping gene, which is unaffected by 
the stimulus utilized in the experiment.  Standard normalization of qRT-PCR analysis 
uses the same reference gene for each experimental analysis including, but not limited to: 
β-actin, cyclophilin-B, and ribosomal 36B4.  As expected, inflammatory gene expression 
relative to ribosomal 36B4 or cyclophilin-B, we observed robust increases in TNF-α, IL-
1β, IL-6, interferon-γ (IFN-γ), IL-10 and MCP-1/CCL2 expression in DIO mice 
compared with lean control mice (Figure 2.6 A-F; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.001).  However, relative to macrophage-specific markers (CD68, F4/80 and CD11c), 
that were a measure of the macrophage content within the VAT, this increase in TNF-α, 
IFN-γ, IL-10 and MCP-1/CCL2 was ameliorated, and in this case a significant decrease 
in their expression was observed when DIO mice were compared with lean control mice 
(Figure 2.6 A, D-F; * p ≤ 0.01,*** p ≤ 0.001), which was not observed relative to 
macrophage marker CD11b (Figure 2.6, A, D-F).  In the case of IL-1β, we observed no  
expression change relative to general macrophage markers, but a significant decrease 
when normalized to M1 activation marker CD11c in DIO mice compared with lean 
control mice (Figure 2.6 B, ***p ≤ 0.001).  Lastly, a slight decrease in IL-6 expression 
was observed relative macrophage-specific genes in the VAT of DIO mice compared 
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with lean controls: however, it does not return to baseline values (Figure 2.6 C).  
Together, these data indicate that the classical markers of M1 activation and AT 
inflammation increase proportionally to the increase in general macrophage markers.  
Thus, the obesity-induced rise in AT inflammation may be because of increased 
macrophage number and proportions within obese VAT, and that the expanding VATM 
population may not be M1 polarized in DIO mice. 
.
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Figure 2.6.  Classical inflammatory gene expression is proportional to macrophage-
specific marker genes in obese VAT.  VAT was isolated from 13-week HFD-
challenged.  RNA was extracted from whole VAT of ND and HFD fed mice and 
subjected to qRT-PCR analysis.  The data is representative of 12 DIO and 12 lean mice.  
Both standard reference housekeeping genes and macrophage-specific marker genes 
(CD68, F4/80, CD11b, and CD11c) were used to normalize the expression of 
inflammatory genes: A. TNF-α, B. IL-1β, C. IL-6, D. MCP-1/CCL2, E. IFN-γ, and F. IL-
10.  The values represent the mean ± SEM.  An unpaired student’s t-test was used for 
comparisons between groups. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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2.5. Discussion 
Over the last decade, the concepts adapted by metabolic research and 
immunology have converged as many studies have reported significant elevations in the 
number of ATMs in VAT and SAT of obese humans and mice that are tightly associated 
with chronic inflammation and IR (56, 252, 261).  We combined gene expression 
profiling with computational analysis of two anatomically distinct AT depots, VAT and 
SAT, to determine whether obese AT inflammation is because of ATM expansion or 
activation.  Consistent with the current model of obesity-induced ATM enrichment, we 
observed significant increases in standard macrophage-specific gene expression (F4/80, 
CD68, CD11b, and CD11c) in DIO mouse VAT compared with lean control mice, 
without changes in the SAT ATM content (Figure 2.2 and Figure 2.3).  As expected,  
classical markers of M1 activation and AT inflammation are increased in DIO mouse 
VAT (but not SAT), however, this increase is proportional to the increase in general 
macrophage markers (Figures 2.4-2.6).  This contrasts with the ex vivo M1 polarization 
model in which inflammatory marker expression is massively increased while general 
macrophage markers are unaffected by macrophage activation.  To this end, the data 
herein suggest that the changes in the overall inflammatory profile of DIO mouse VAT is 
mainly because of quantitative increases of the ATM population and not because of 
qualitative changes in macrophage activation states.   
In human obesity, it is understood that body type and specific differences in fat 
distribution affect whole-body metabolism, as the AT location is tightly associated with 
inflammation; VAT being associated with a more adverse risk profile than SAT for the 
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metabolic syndrome and T2DM (61).  The anatomical location of VAT versus SAT is 
essential to their involvement in metabolic disease progression and IR, as expansion of 
VAT in humans contributes to increased hepatic delivery of FFAs because of increased 
AT lipolysis, thus driving hepatic IR (161).  In contrast, the FFAs released from SAT are 
delivered into peripheral circulation, reducing their affect on hepatic IR (161).  TZD 
treatment to improve insulin sensitivity increases total fat mass mostly in SAT fat stores, 
and this increased SAT, especially in the lower extremities, is associated with a decreased 
risk of disturbed glucose metabolism and dyslipidemia, independent of VAT expansion 
(209, 218).  This indicates that SAT plays a protective role in the context of metabolic 
disease.  Thus, it is not surprising that in our study the inflammatory signature of the SAT 
was unchanged with limited macrophage infiltration when compared with the VAT from 
the same DIO mice (Figure 2.2 and Figure 2.3).  This suggests that not only is the SAT 
resistant to HFD-induced inflammation, but that VAT and SAT are anatomically distinct 
AT depots that respond differently to DIO.  Thus, it is possible that the contrasting affects 
of SAT and VAT on systemic insulin sensitivity may be due to dissimilar tissue 
microenvironments between the two depots, indicating a correlation between VAT 
inflammation and disturbed glucose tolerance in DIO mice (Figure 2.1 and Figure 2.2 A 
and C).   
These data encouraged the endeavor to expand upon the standard model of AT 
inflammation and determine whether the inflammatory profile of the DIO mouse VAT is 
because of obesity-induced macrophage enrichment or activation. We predicted that our 
data would coincide with the initial paradigm of obesity-induced macrophage activation 
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in VAT and we hypothesized that DIO causes robust increases in VAT inflammatory 
gene expression (86, 252, 261).  We used LPS-stimulated macrophages as an ex vivo 
model of macrophage activation, because the literature indicates that VATMs display the 
characteristic phenotype of M1 macrophages (Figure 2.4) (134-136, 142).  We report 
significant elevations in pro-inflammatory gene expression in LPS-stimulated 
macrophages compared with unstimulated cells, without changes in macrophage-specific 
marker genes, like F4/80; thus permitting their use as a measure of macrophage content 
within obese AT (Figure 2.2 A and Figure 2.4).  Although we observed a significant 
enrichment of these macrophage marker genes in DIO mouse VAT compared with lean 
control mice, the genomic analysis revealed little or no changes in the classical 
inflammatory markers of M1 activation and AT inflammation (Figure 2.4 and Figure 
2.5). Increased M1 polarization of VATMs should result in disproportionately higher 
expression of inflammatory markers (TNF-α, IL-6, IL-1β) in DIO mouse VAT compared 
to common M1/M2 markers.  Unexpectedly, the genomics analysis revealed that these 
inflammatory cytokines were unchanged despite significant increases in macrophage 
marker gene expression suggesting that the expanded ATM population may not be M1 
polarized (Figure 2.5).  
Although our genomics analysis indicates an inconsistency with published data 
regarding the inflammatory profile of VAT, it is important to note that the time-course of 
high fat feeding is in accordance with the recent literature.  The mice used in this study 
were challenged with a HFD for 13-weeks and demonstrated decreased glucose tolerance 
and hyperinsulinemia (Figure 2.1 B-C).  Lee et al. assessed the temporal events 
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underlying IR development during high fat feeding and found that lipotoxicity was causal 
for short-term diet-induced IR, while chronic inflammation emerged as a more dominant 
mechanism once obesity is established by long-term HFD challenge (128).  Even though 
lipotoxicity may not be the driving force for diet-induced IR in the long-term, in vitro 
treatment of macrophages with saturated FAs or conditioned medium from adipocyte cell 
lines increased M1 gene expression providing evidence that lipids released from 
adipocytes drives M1 polarization in obese AT (211, 225, 262).  It is also well established 
that macrophages infiltrate obese AT to internalize cell debris from necrotic adipocytes 
and studies comparing the histology of lean and obese VAT illustrates the formation of 
CLS around these dying adipocytes (137, 252).  These CLS are not solely infiltrating 
macrophages, as a recent study from our laboratory discovered that proliferation in situ is 
an important process by which macrophages accumulate in inflamed AT of both genetic 
and DIO mouse models of obesity (1).  In agreement with this, the histology from DIO 
mouse VAT illustrated significant enrichment of an F4/80+ macrophage population with 
the appearance of CLS when compared with lean control mice (Figure 2.3 C and D).  It 
was also recently discovered that macrophages aid in sequestering FAs released from 
dying adipocytes, giving rise to foam cell formation within obese AT (118, 188, 252).  
The accumulation of lipid species and LDs in ATMs are observed in classically activated 
M1 macrophages, introducing an alternative role of M1 ATMs in obesity (188).  This 
discovery coincides with our proposed idea that expanded population of ATMs may act 
in a non-inflammatory role, as our genomics analysis reveal minimal or no changes in 
inflammatory gene expression, despite macrophage gene enrichment. 
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We further explored this idea by assessing the changes of inflammatory gene 
expressions relative to macrophage specific markers to distinguish between increased 
macrophage activation or increased macrophage content in DIO mouse VAT by qRT-
PCR analysis (Figure 2.6).  Classical analysis of qRT-PCR data is dependent upon the 
normalization of each gene of interest to an invariant endogenous control; thus, the 
quality of the normalized data cannot be better than the quality of this reference gene.  
Importantly, these reference genes are unaffected by experimental stimuli and in this case 
being DIO and LPS-driven macrophage activation (238).  In our laboratory, 36B4 and 
cyclophilin-B have proven to be reliable references genes in multiple cell types and 
tissues including AT.  Thus, we used these genes to confirm published data, but also used 
standard macrophage-specific genes that signify the macrophage content within the AT to 
determine proportional changes in inflammatory gene expression.  As expected, relative 
to 36B4 or cyclophilin-B, we observed robust increases in the expression of TNF-α, IL-
1β, IFN-γ, IL-10 and MCP-1/CCL2 when DIO mice are compared with lean control mice 
(Figure 2.6).  However, relative to macrophage marker genes F4/80, CD68, and CD11c, 
a dramatic overall decrease in expression was observed (Figure 2.6).  Furthermore, a 
more robust decrease was evident when DIO mouse VAT expressions were compared 
with lean control mice (Figure 2.6).  Interestingly, inflammatory gene expressions were 
decreased when normalized to CD11b compared with 36B4 or cyclophilin-B; however, 
no decrease was evident when compared with lean control mice (Figure 2.6).  This 
observation may be because CD11b is not solely an ATM marker; it is also expressed by 
many leukocytes including monocytes, neutrophils, granulocytes, dendritic cells, NK 
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cells and a subset of CD8+ T cells (29).  Recent literature suggest that many subtypes of 
immune cells are responsible for AT inflammation and are required to control both the 
macrophage content and the polarization state within obese AT (115, 162-163, 259).  
Thus, CD11b may not be an appropriate gene for normalization of macrophage 
infiltration into the VAT of DIO mice.  Conversely, CD11c is a classic marker used to 
characterize M1-polarized ATMs in the AT of obese mice.  Our data illustrates dramatic 
decreases in inflammatory gene expression when normalized to this M1 macrophage 
specific gene (63, 136).  Consistent with these findings, a recent publication by Xu et al., 
determined that the expression of most inflammatory genes was unchanged between 
purified CD11c- and CD11c+ ATM populations in an unbiased analysis of lean, diet-
induced and genetically obese mice (262).  This parallels our study because although 
some M1 genes were increased, most of the M1 genes (TNF-α, IL-1β, IL-6) were reduced 
when normalized to macrophage-specific genes, indicating a lack of ATM activation in 
DIO mouse AT (262).  Therefore, our data suggest that the increased inflammatory gene 
expressions in AT is due to an increase in overall macrophage cell number within the 
VAT and not indicative of ATM polarization toward a classical M1 phenotype.   
Lastly, we explored the possibility of macrophage plasticity and that these 
macrophages may be in an alternative state of activation.  Alternatively activated M2 
macrophages predominate in the AT of lean mice and function to maintain tissue 
integrity by their involvement in tissue repair and extracellular matrix/remodeling (135-
136, 188).  ATMs from 5-week old ob/ob mice express high levels of genes involved in 
extracellular matrix/remodeling and anti-inflammatory macrophage markers (Arg1 and 
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CD209e) indicating M2-macrophage involvement in mild obesity as expression levels are 
reduced in 16-week old severely obese ob/ob mice (188).  Our data regarding M2 
macrophage activation within the obese AT was inconclusive and requires further 
analysis (data not shown).  More recently, however, it was discovered that the AT 
microenvironment does not activate or drive inflammatory polarization of ATMs per se, 
but induces a differentiation program in which lipid uptake and lysosome biogenesis are 
coordinately regulated (262).  In conjunction with these results, liposomal-mediated 
ATM depletion increased circulating FFA concentrations (Table 3.1), confirming their 
role in lipid uptake and suggesting that AT lipid metabolism may not be confined to the 
adipocyte, but that ATMs also play a role (118).   
The  data provided herein demonstrate the complexities of ATM function in DIO 
mouse VAT and encourage the on-going studies to understand these complex roles of 
ATMs in obesity and inflammation.  Our data suggest that relative changes in the overall 
inflammatory signature of VAT is induced by quantitative increases in the number of 
macrophages enriched in obese AT rather than qualitative changes in ATM polarization 
to a classical inflammatory M1-like state (Figure 2.7).  These data also do not disqualify 
the current model in which factors secreted from the AT can recruit and activate both 
resident and infiltrating macrophages or that inflammatory factors secreted from ATMs 
are largely responsible for the metabolic consequences that accompany obesity.  This 
study, however, does indicate that although DIO mouse VATMs are enriched in number, 
this expanding macrophage population of ATMs may not be present with the purpose to 
exacerbate AT inflammation; VATM populations may include cells with alternative,
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possibly beneficial functions in obese AT to serve alternative and trophic functions, even 
in the obese state in mice. 
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Figure 2.7. VAT inflammation is increased relative to the increased macrophage 
content in obese AT.  Lean and insulin sensitive AT maintains normal metabolic 
function and contains resident tissue macrophages with a characteristic phenotype of 
alternative activation.  As obesity develops, adipocytes undergo hypertrophy owing to 
increased TG storage.  As the expansion limit of AT is reached, triglyceride storage and 
metabolic dysfunction occur as well as insulin resistance.  Obese IR VAT has increased 
levels of immune cells and expansion of ATM populations that contribute to the 
increased inflammatory signature of obese IR VAT.  However, the VAT inflammation is 
increased proportionally to the changes in increased ATM content indicating that the 
quantitative changes in macrophage cell number and not qualitative changes in the 
activation state of the expanding ATM populations promote the transition to an 
inflammatory tissue environment in obese mouse VAT.  
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2.6. Experimental Procedures 
 
Animals, Diets and Treatments 
Wild type male C57Bl6/J mice were obtained from the Jackson Laboratory (Bar Harbor, 
ME).  Animals used for HFD studies were fed standard chow diet (LabDiet PicoLab 
5053, Purina Mills, St. Louis, MO) until 8 weeks of age and then divided into two 
groups; one was fed chow diet and the other group was fed HFD (45 kcal% fat, D12451, 
Research Diets, New Brunswick, NJ) for 13 weeks. Animals were housed in the 
University of Massachusetts (UMass) Medical School Animal Medicine facility with a 
12-hour light/dark cycle and given ad libitum access to food and water.  Animals were 
weighed weekly for the duration of the diet study.  IPGTT was performed as previously 
described (187).  The AUC for the IPGTT was calculated using the trapezoidal method 
(187).  At the completion of the HFD, mice were fasted for 6 hours and then euthanized 
with CO2 inhalation and bilateral pneumothorax.  All of the experiments were performed 
in accordance with protocols approved by the Institutional Animal Care and Use 
Committees (IACUC) at UMass Medical School. 
 
Sample Storage 
SAT and VAT were harvested and snap frozen in liquid nitrogen for RNA or paraffin 
embedded for immunohistochemical analysis.  Blood was drawn via the retro-orbital 
sinus into EDTA tubes; plasma was centrifuged at 10,000 rpm for 10 min and aliquotted.  
All of the samples were stored at -80C.     
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Primary cell isolations and culture   
10-week old C57BL6/J male mice were i.p. injected with 4% thioglycollate broth 
(Sigma–Aldrich).  At 5 days following the injection, mice were euthanized by CO2 
inhalation, and the peritoneal cavity was washed with 5 ml ice-cold PBS to isolate PECs.  
Peritoneal fluid was filtered through a 70 μm diameter pore nylon mesh and centrifuged 
at 270 x g for 10 min.  The pellet was first treated with red blood cell lysis buffer (8.3 g 
of NH4Cl, 1.0 g of KHCO3 and 1.8 ml of 5% EDTA) and then plated in DMEM 
(Dulbecco's modified Eagle's medium) supplemented with 10% (v/v) FBS (fetal bovine 
serum), 50 μg/ml streptomycin and 50 units/ml penicillin.  At 24 hours after isolation, 
PECs were either untreated or treated with LPS for 6 hours. 
 
RNA isolation and quantitative RT-PCR  
Whole VAT and SAT were isolated, snap frozen in liquid nitrogen, and stored at −80°C.  
Tissues were homogenized using the gentleMACs Dissociator (Miltenyi Biotec) and 
RNA was isolated following the manufacturer’s protocol (TriPure, Roche).  RNA was 
isolated from cultured PECs according to the manufacture’s protocol.  Precipitated RNA 
was treated with DNAse (DNA-free, Life Technologies) prior to reverse transcription 
(iScript Reverse transcriptase, BioRad).  SYBR green quantitative PCR (iQ SYBR green 
supermix, BioRad) was performed on the BioRad CFX97. Expression was normalized to 
the ribosomal gene 36B4 or standard macrophage marker genes (F4/80, CD68, CD11b, 
CD11c) and expressed relative to the expression of ND mice or untreated PECs.  The 
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internal loading controls 36B4 or cyclophilin-B did not change with diet or LPS 
treatment.  Melt curve analysis was performed to determine PCR reaction product 
specificity.  Primer sequences were designed with Primer Bank.  Primer sequences are as 
follows: 36B4: 5’- TCCAGGCTTTGGGCATCA-3’, 3’- 
CTTTATCAGCTGCACATCACTCAGA-5’; CD11b: 5’-
CCATGACCTTCCAAGAGAATGC-3’, 3’-ACCGGCTTGTGCTGTAGTC-5’;  CD11c: 
5’- CTGGATAGCCTTTCTTCTGCTG-3’, 3’- GCACACTGTGTCCGAACTCA-5’; 
F4/80: 5’- CCCCAGTGTCCTTACAGAGTG-3’, 3’- GTGCCCAGAGTGGATGTCT-5’; 
CD68: 5’-GGACCCACAACTGTCACTCA-3’, 3’-AAGCCCCACTTTAGCTTTACC-
5’; IL1-β: 5’- GCAACTGTTCCTGAACTCAACT-3’, 3’- 
ATCTTTTGGGGTCCGTCAACT-5’; TNF-α: 5’-CAGGCGGTGCCTATGTCTC-3’;  
IL-6: 5’- TAGTCCTTCCTACCCCAATTTCC-3’, 3’- 
TTGGTCCTTAGCCACTCCTTC-5’; IFN-γ: 5’-AATGAACGCTACACACTGCATC-
3’, 3’-CCATCCTTTTGCCAGTTCCTC-5’; MCP-1/CCL2: 5’- 
TTAAAAACCTGGATCGGAACCAA-3’, 3’- GCATTAGCTTCAGATTTACGGGT-5’ 
 
Histology and Immunohistochemistry  
AT samples (n = 3 per group) from lean and DIO mice were fixed in 4% formalin for 
immunohistochemistry.  Briefly, samples were embedded in paraffin, sectioned, and 
stained with rat anti-mouse F4/80 antibodies (ABd Serotec, Raleigh, NC) (1:40 dilution).  
Staining was visualized with HRP-linked rabbit anti-rat secondary antibodies.  Staining 
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with the secondary antibodies alone was performed as a negative control.  Images were 
taken with a Zeiss Microscope and PixeLINK SE Software 
 
Microarray Analysis  
RNA was isolated from SAT, VAT and PECs as previously described. RNA 
concentrations were determined using a Nanodrop 2000 Spectrophotometer (Thermo 
Fisher, Willmington, DE). The RNA quality was assessed using an Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA). Only samples with a RNA 
Integrity Number > 7.5 and normal 18 and 28s fractions on microfluidic electrophoresis 
were used.  In total, 250 ng total RNA was used as template for cDNA synthesis and in 
vitro transcription using the Ambion WT Expression kit (Ambion, Carlsbad, CA).  
Second strand cDNA was then labeled with the Affymetrix WT Terminal Labeling kit 
and samples were hybridized to Affymetrix Mouse Gene 1.0 ST arrays (Affymetrix, 
Santa Clara, CA).  Gene chip expression array analysis for individual genes was 
performed as previously described (230), filtering for p < 0.05 and a fold change > 2.  
Four biological replicate hybridizations per genotype and diet and 3 biological replicates 
per in vitro condition were performed for a total of 18 hybridizations.  Robust multi-array 
average (RMA) was adopted in the UMASS Microarray Computational Environment 
(MACE) to preprocess raw oligonucleotide microarray data.  The preprocessed data are 
stored as base 2 log transformed real signal numbers and are used for fold change 
calculations and statistical tests and to determine summary statistics.  Mean signal values 
and standard deviations are computed for each gene across triplicate experiments and 
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stored in the database.  The fold change of expression of a gene in two experiments is the 
ratio of mean signal values from these experiments and is always a number greater than 
one.  If the ratio is less than one, the negative value of the inverse ratio is stored as fold 
change.  All down regulated genes therefore have a negative fold change value and up 
regulated genes have a positive fold change. In both cases this value is greater or equal 
than one.  To determine differential gene expression in two hybridization experiments, 
MACE internally conducts a student’s t-test with the expression signal values of the two 
hybridizations for all genes in the set.  The t-test value and test p-value are stored in 
MACE and can be queried through the MACE user interface.   
 
Statistical Analysis 
All of the values are demonstrated as the mean ± SEM.  For experiments other than the 
microarray analyses, a student’s t-test for two-tailed distributions with equal variances 
was used for comparison between 2 groups.  Differences less than p < 0.05 were 
considered to be significant.  The AUC for the IPGTT was calculated using a student’s t-
test after performing a baseline correction for the basal glucose values for each individual 
mouse.  All of the data were entered into Microsoft Excel, and statistical analyses were 
performed with Graph Pad Prism 5.0. 
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3.1. Abstract 
Non-alcoholic fatty liver disease is prevalent in human obesity and T2DM, and is 
characterized by increases in both hepatic TG accumulation (denoted as steatosis) and 
expression of pro-inflammatory cytokines such as IL-1β.  We report here that the 
development of hepatic steatosis requires IL-1 signaling, which upregulates Fas to promote 
hepatic lipogenesis.  Using clodronate liposomes to selectively deplete liver KCs in ob/ob 
mice, we observed remarkable amelioration of obesity-induced hepatic steatosis and 
reductions in liver weight, TG content and lipogenic enzyme expressions.  Similar results 
were obtained with DIO mice, although VATM depletion also occurred in response to 
clodronate liposomes in this model.  There were no differences in the food intake, whole 
body metabolic parameters, serum β-hydroxybutyrate levels or lipid profiles due to 
clodronate-treatment, but hepatic cytokine gene expressions including IL-1β were 
decreased.  Conversely, primary mouse hepatocyte treatment with IL-1β significantly 
increased TG accumulation and Fas expression.  Furthermore, the administration of IL-1Ra 
to DIO mice markedly reduced obesity-induced steatosis and hepatic lipogenic gene 
expression.  Collectively, our findings suggest that IL-1β signaling upregulates hepatic 
lipogenesis in obesity, and is essential for the induction of pathogenic hepatic steatosis in 
obese mice.  
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3.2. Introduction 
The prevalence of obesity represents a fully fledged epidemic as greater than 300 
million adults are clinically obese worldwide (91).  Obesity is a prominent risk factor for 
IR, T2DM, NAFLD and other metabolic disorders because it impairs systemic metabolic 
homeostasis.  A major hallmark of obesity is AT dysfunction, which is characterized by a 
chronic state of low-grade inflammation, and by a decreased ability of adipocytes to 
efficiently store excess nutrients and lipids as TGs (77, 91, 267).  This in turn is thought 
to increase circulating FFAs and ectopic lipid deposition within insulin sensitive tissues, 
such as muscle and liver, causing IR.  The intracellular hepatic lipid accumulation and 
subsequent formation of LDs within hepatocytes can activate resident tissue 
macrophages, otherwise denoted as KCs, which release pro-inflammatory cytokines, 
including TNF-α, IL-6 and IL-1β (2, 229, 232).  This inflammation enhances NAFLD 
progression to fibrosis, cirrhosis, chronic liver disease, and exacerbates IR (2, 165, 229, 
232, 252) 
Recently, macrophage depletion techniques have been used to determine the 
effects of macrophage function on insulin sensitivity.  Conditional macrophage ablation 
in combination with transgenic and gene deletion mouse models have demonstrated that 
CD11c+ macrophages, Nlrp3-inflammasome components and pro-inflammatory cytokines 
promote glucose intolerance and IR in both DIO and genetic mouse models of obesity (9, 
54, 144, 179, 237, 251, 254).  Drug-encapsulated liposome administration has been 
utilized to selectively deplete KCs and VATMs to improve glucose and insulin sensitivity 
and reduce hepatic steatosis in DIO mouse models (18, 54, 239).   Lastly, anti-cytokine 
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therapy or pharmacological blockade of pro-inflammatory cytokines has also been 
successful in improving systemic glucose and insulin tolerance as well as β-cell function 
in obese mice and human subjects (45, 174, 237).  One such drug is Anakinra (Kineret), 
which is recombinant IL-1Ra that blocks IL-1 signaling via the IL-1 receptor (45, 125, 
205).  However, previous work utilizing clodronate liposomes to deplete KCs in DIO 
mice have reported contradictory conclusions regarding the involvement of KCs in 
obesity-driven steatosis, clouding the roles of these cells in this syndrome (31, 54, 124, 
223). 
The present studies were designed to clarify this issue and elucidate the 
mechanism by which KC-derived pro-inflammatory cytokines regulate whole body and 
hepatic lipid metabolism in obesity.  We targeted KCs in vivo by i.p. clodronate liposome 
administration in two animal models of obesity: DIO and ob/ob mice.  The results herein 
demonstrate that clodronate liposome-mediated KC depletion, regardless of VATM 
content in both DIO and ob/ob mice, abrogated hepatic steatosis by reducing hepatic de 
novo lipogenic gene expression.  Additionally, we observed significant decreases in 
hepatic inflammation and hypothesized that IL-1β may be responsible for the increased 
TG accumulation in obese mouse livers.  In agreement with this hypothesis, IL-1β 
treatment increased hepatic lipid deposition and Fas expression in primary mouse 
hepatocytes. Furthermore, the pharmacological inhibition of IL-1 signaling by 
administration of recombinant human IL-1Ra to DIO mice attenuated obesity-induced 
hepatic steatosis and reduced hepatic lipogenic gene expression.  These data illustrate the 
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importance of IL-1β in obesity-driven hepatic steatosis, and suggest that liver 
inflammation controls hepatic lipogenesis in obesity. 
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3.3. Results 
Clodronate liposome-mediated KC depletion ameliorates hepatic steatosis in DIO 
and ob/ob mice. 
Resident tissue macrophages aid in tissue homeostasis, but obesity can promote 
low-grade inflammation in insulin sensitive tissues.  Conflicting literature has 
complicated our understanding of the role of KCs and hepatic inflammation in lipid 
homeostasis in obese mouse livers (19, 31, 54, 124).  Thus, we sought to investigate the 
mechanism whereby KCs and KC-derived cytokines regulate whole body and hepatic 
lipid metabolism in two mouse models of obesity after clodronate liposome-mediated KC 
depletion.  We employed a 2-dose injection scheme of clodronate liposomes (250 mg/kg) 
or an equivalent volume of control PBS liposomes to deplete KCs in vivo (Figure 3.1).  
Liposomes were injected i.p. into DIO or ob/ob mice every 3-days over the course of 6 
days during the final week of a 13-week HFD challenge.  It has been established that 
short-term diet-induced IR is caused by lipotoxicity, which occurs after only 3 days of 
high fat feeding (128).  Chronic inflammation emerges as a more dominant mechanism 
once obesity is established by a long-term, 10-week high fat feeding (128).  Therefore, 
late phase injections were utilized in this study.  We observed no changes in the total 
animal body weight of PBS or clodronate liposome-treated mice upon completion of the 
experiments (Figure 3.2 and 3.6 Legends).     
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Figure 3.1.  Injection scheme for intraperitoneal administration of clodronate 
liposomes into obese mice.  13-week HFD-challenged WT mice or 8-week old ob/ob 
mice were injected with 2 doses of 250 mg/kg clodronate-encapsulated liposomes or 
PBS-liposomes i.p. for 6 days in a 3-day interval.  WT mice were injected during the 
final week of HFD challenge.  Mice were fasted on day 6 for 6 hours at the start of the 
light cycle and blood was collected via retro-orbital sinus after isoflurane anesthesia. The 
tissues were collected immediately after sacrifice by CO2 asphyxia and cervical 
dislocation. 
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Previous studies employing i.p. clodronate liposome administration in DIO mice 
report inconsistencies in the ability to deplete both KCs and VATMs from the liver and 
VAT, respectively (19, 31, 54).  To first confirm the efficiency of macrophage depletion 
within the clodronate-treated DIO mouse VAT, we isolated the SVF from the VAT on 
day 6 from animals that had been injected with clodronate or an equivalent volume of 
PBS liposomes.  Cells were characterized by FACS analysis and macrophages were 
identified as cells that were positive for CD11b and F4/80 antigen and negative for the 
eosinophil marker Siglec F (227, 260).  In PBS liposome-treated DIO animals, 
approximately 27% of Siglec F-negative SVF cells were positive for both CD11b and 
F4/80 (Figure 3.2 A-B).  However, in clodronate-treated DIO animals, this percentage 
decreased to 14%, which was a 45% decrease compared with PBS liposome-treated mice.  
Moreover, the percentage of the M1-type inflammatory macrophage marker, CD11c, of 
the total SVF cells was reduced 68% in clodronate-treated mice compared with PBS 
liposome-treated mice (Figure 3.2 A-B; p < 0.05).  As assessed by qRT-PCR, we 
observed an 82% and 65% decrease in F4/80 and CD11c gene expression, respectively, 
in clodronate-treated DIO mouse livers compared with control animals (Figure 3.2 D; p 
≤ 0.01, 0.05).  We also isolated SAT, lung and spleen to determine if clodronate-
liposomes are capable of depleting resident tissue macrophages within other tissues.  We 
observed a reduction in splenic macrophage content without affecting macrophages 
present within the lungs or SAT of clodronate-treated mice compared with PBS 
liposome-treated control mice (data not shown).  We also isolated primary hepatocytes 
from clodronate-treated DIO mice via perfusion and observe no changes in pro-apoptotic 
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gene expression, indicating that the hepatocellular apoptosis pathway is unaffected by 
clodronate liposome treatment (Figure 3.3 A-B).  Taken together, these results indicate 
that both macrophages in VAT and KCs in the liver of DIO mice were greatly reduced by 
the clodronate treatments. 
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Figure 3.2.  Clodronate liposomes effectively deplete KCs and VATMs of DIO mice.   
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Figure 3.2.  Clodronate liposomes effectively deplete KCs and VATMs of DIO mice. 
13-week HFD-challenged WT mice were injected with 2 doses of clodronate liposomes 
(250 mg/kg) or PBS liposomes i.p. over 6 days with a 3-day interval during the last week 
of high fat feeding.  We observed no changes in the total animal body weight of PBS 
liposome-treated mice (42.4 ± 1.8 to 41.6 ± 1.9) or clodronate-treated mice (44.01 ± 2.2 
to 41.5 ± 2.6).  VAT SVF was isolated and FACS analysis was performed.  A.) Upper 
panels, PBS liposome-treated mice.  Lower panels, clodronate-treated mice.  Left panels, 
SiglecF-negative, CD11b- and F4/80-positive cells.  Right panels, CD11c-positive cells.  
Panels are representative of 6 animals per group.  B.)  The percentage of the total number 
of cells counted for both CD11b- and F4/80-positive cells and CD11c-positive cells in the 
VAT of DIO mice.  RNA was extracted and qRT-PCR was performed for standard 
macrophage markers (F480, CD11c) in C.) VAT and D.) liver of DIO mice.  The values 
represent the mean ± SEM.  An unpaired student’s t-test was used for comparisons 
between groups. * p ≤ 0.05, ** p ≤0.01. 
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Figure 3.3.  Pro-apoptotic genes that regulate intrinsic cell-death are unchanged in 
primary hepatocytes isolated from clodronate-treated DIO mice.  16-week HFD-
challenged WT mice were injected with 2 doses of clodronate liposomes (250 mg/kg) or 
PBS liposomes i.p. over 6 days with a 3-day interval during the last week of high fat 
feeding.  Hepatocytes were isolated via perfusion and RNA was extracted for qRT-PCR 
analysis of pro-apoptosis gene expression A.) Bax and B.) Bak.  The values represent the 
mean ± SEM.  An unpaired student’s t-test was used for comparisons between groups 
(n.s.).  
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Upon dissection of the mice, we noted a macroscopic reduction in the steatotic 
appearance of the livers of clodronate-treated DIO animals compared with PBS 
liposome-treated control mice.  In agreement with this observation, DIO mouse liver 
weights as a percentage of total animal body weight were decreased by 19% in 
clodronate-treated mice compared with PBS liposome-treated mice (Figure 3.4 B; p ≤ 
0.01).  Clodronate-treated DIO mice displayed a significant reduction of liver TGs when 
compared with PBS liposome-treated mice, as observed microscopically by H&E and 
Oil-Red-O staining (Figure 3.4 A).  Quantitative analysis revealed that KC depletion 
resulted in a 62% decrease in hepatic TG content in clodronate-treated DIO mice 
compared with the PBS liposome-treated controls (Figure 3.4 C; p ≤ 0.05).  Clodronate-
treated mice displayed no fibrotic changes or indications of necrosis compared with PBS 
liposomes-treated mice, as observed microscopically by masson’s trichrome and TUNEL 
staining (Figure 3.5 A-D).  These data demonstrate that clodronate-mediated KC and 
VATM depletion results in a remarkable reduction in hepatic TG content and 
amelioration of obesity-induced steatosis in DIO mice 
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Figure 3.4.  Clodronate liposome-mediated KC and VATM depletion ameliorates 
hepatic steatosis in DIO mice. 13-week HFD-challenged WT mice were injected with 2 
doses of clodronate liposomes (250 mg/kg) or PBS liposomes i.p. over 6 days with a 3-
day interval during the last week of high fat feeding.  A.) DIO mouse livers were isolated, 
fixed in 10% formalin, embedded in paraffin, and stained with H&E or frozen in OCT 
and stained with Oil-Red-O to assess steatosis.  Images are representative of 12-16 
animals at 10x and 20x magnification.  B.) DIO mouse livers were weighed and the data 
is represented as a percentage of the total body weight.  C.) The total TGs were extracted 
and normalized to tissue weight.  The values represent the mean ± SEM.  An unpaired 
student’s t-test was used for comparisons between groups. * p ≤ 0.05, ** p ≤ 0.01. 
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Figure 3.5. Livers isolated from clodronate-treated DIO mice display no evidence of 
necrosis or fibrosis.  13-week HFD-challenged WT mice were injected with 2 doses of 
clodronate liposomes (250 mg/kg) or PBS liposomes i.p. over 6 days with a 3-day 
interval during the last week of high fat feeding.  DIO mouse livers were isolated, fixed 
in 10% formalin, embedded in paraffin, and stained with A-B.) TUNEL to assess necrosis 
or C-D.) masson’s trichrome to assess fibrotic changes and overall hepatic health.  
Images are representative of 4 animals per group at 10x and 20x magnification.    
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In order to determine whether these results would also apply to a genetic model of 
obesity, we used the leptin-deficient ob/ob mouse in a subsequent set of experiments. 
Unexpectedly, no reduction in ob/ob mouse VATM content was observed after 
clodronate treatment as assessed by either FACS analysis or qRT-PCR (Figure 3.6 A-C).  
Thus, clodronate treatment depleted VATMs in the DIO mouse model of obesity, but not 
in ob/ob mice when compared with their respective PBS liposome-treated controls.  
However, we observed a 94% and 60% decrease in F4/80 and CD11c gene expression, 
respectively, in ob/ob mouse livers after clodronate treatment compared with PBS 
liposome-treated mice (Figure 3.6 D; p ≤ 0.001, 0.05).  These data illustrate that 
clodronate administration can effectively and efficiently deplete KCs from the livers of 
both DIO and ob/ob mice, whereas VATM depletion only occurs in the DIO mouse 
model.  This finding is particularly insightful because ability to deplete KCs in the 
absence of VATM depletion in ob/ob mice provides a novel model for determining the 
KC-mediated affects on obesity-induced hepatic steatosis. 
In spite of the fact that cell depletion due to clodronate was restricted to KCs and 
not VATMs in the ob/ob mouse model, a similar reduction in the steatotic appearance of 
the livers of clodronate-treated ob/ob animals compared with PBS liposome-treated 
animals was apparent (Figure 3.7).  In agreement with this observation, ob/ob mouse 
liver weights as a percentage of total body weight were decreased 30% in the clodronate-
treated animals compared with PBS liposome-treated animals (Figure 3.7 B; p ≤ 0.01).  
Microscopic analysis of livers stained with H&E and Oil-Red-O revealed a significant 
reduction of liver TGs in clodronate-treated ob/ob mice compared with the PBS 
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liposome-treated mice (Figure 3.7 A).  Quantification of hepatic TG content revealed 
that KC depletion resulted in a 45% decrease in hepatic TGs in clodronate-treated ob/ob 
mice compared with the PBS liposome-treated controls (Figure 3.7 C; p ≤ 0.05).  
Collectively, these data illustrate that clodronate liposome-mediated KC depletion, in two 
mouse models of obesity, results in a marked reduction of hepatic TG content and 
amelioration of obesity-induced hepatic steatosis.  Notably, this reduction of hepatic TGs 
occurs independently of VATM depletion in the ob/ob mouse model, demonstrating the 
importance of KCs in the regulation of hepatic lipid metabolism. 
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Figure 3.6. Clodronate liposomes deplete KCs but not VATMs in ob/ob mice. 
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Figure 3.6.  Clodronate-encapsulated liposomes deplete KCs but not VATMs in 
ob/ob mice.   8-week ob/ob mice were injected with 2 doses of clodronate liposomes (250 
mg/kg) or PBS liposomes by i.p. for 6 days with a 3-day interval.  We observed no 
changes in the total animal body weight of PBS liposome-treated mice (44.2 ± 0.7 to 45.2 
± 0.6) or clodronate -treated mice (41.9 ± 1.4 to 41.1 ± 1.7).  VAT SVF was isolated and 
FACS analysis was performed.  A.) Upper panels, PBS liposome-treated mice.  Lower 
panels, clodronate-treated animals.  Left panels, SiglecF-negative, CD11b- and F4/80-
positive cells. Right panels, CD11c-positive cells. Panels are representative of 4-6 
animals per group.  B.) The percentage of the total number of cells counted for both 
CD11b- and F4/80-positive cells and CD11c-positive cells in the VAT of ob/ob mice.  
RNA was extracted and qRT-PCR was performed for standard macrophage markers 
(F480, CD11c) in C.) VAT and D.) liver of ob/ob mice.  The values represent the mean ± 
SEM. An unpaired student’s t-test was used for comparisons between groups. * p ≤ 0.05, 
*** p ≤ 0.001. 
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Figure 3.7.  Clodronate liposome-mediated KC depletion ameliorates hepatic 
steatosis in ob/ob mice.  8-week old male ob/ob mice were injected with 2 doses of 
clodronate liposomes (250 mg/kg) or PBS liposomes by i.p. over 6 days with a 3-day 
interval.  A.) The ob/ob mouse livers were isolated, fixed in 10% formalin, embedded in 
paraffin, and stained with H&E or frozen in OCT and stained with Oil-Red-O to assess 
steatosis.  The images are representative of 7-10 animals at 10x and 20x magnification.  
B.) The ob/ob mouse livers were weighed and the data is represented as a percentage of 
the total body weight. C.) The total TGs were extracted and normalized to tissue weight. 
The values represent the mean ± SEM. An unpaired student’s t-test was used for 
comparisons between groups. * p ≤ 0.05, *** p ≤ 0.001. 
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Clodronate liposome-mediated KC depletion decreases hepatic lipogenic gene 
expression in DIO and ob/ob mice.   
The striking reduction of hepatic TGs in the clodronate-treated mice could be 
mediated by different pathways, including increased fatty acid oxidation, increased 
VLDL secretion, reduced influx of non-esterified FFAs from AT, and/or reduced hepatic 
DNL (46).  To assess whether clodronate liposome treatment affected basal whole-body 
metabolic parameters, mice challenged with a HFD for 13-weeks and subjected to 
metabolic cage analysis throughout the duration of clodronate or PBS liposome 
treatment.  We determined that there were no differences in the food consumption, water 
intake or physical activity between groups throughout the course of liposome treatment 
(Table 3.1).  There were also no differences in the EE, respiratory exchange ratio (RER), 
or serum β-hydroxybutyrate levels in clodronate-treated DIO mice compared with PBS 
liposome-treated control mice (Table 3.1).  Moreover, there were no changes in serum 
lipoprotein concentrations (Table 3.1) or the expression of genes promoting fatty acid 
oxidation, including PPARα or carnitine palmitoyltransferase-1a (Cpt1a) in clodronate-
treated DIO or ob/ob mouse livers compared with PBS liposome-treated mice (Figure 
3.8).  These data suggest that whole body fatty acid oxidation is not affected by 
clodronate-treatment in DIO mice, and therefore we explored whether hepatic lipogenesis 
contributed to the reduced hepatic TG content in the clodronate-treated mice.  Evaluation 
of liver samples by qRT-PCR analysis revealed reduced PPARγ expression and 
downstream genes that encode lipogenic enzymes including scd1, dgat, fasn, and acc2 as 
well as cell death-inducing DFFA-like effector A (cidea), which contributes to LD 
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formation in both DIO and ob/ob clodronate-treated mice (Figure 3.9 A-B; p ≤ 0.05).  
Consistent with these data, a 40% decrease in Fas protein expression was observed in the 
livers of the clodronate-treated DIO mice compared with PBS-liposome treated mice 
(Figure 3.9 C-D; p ≤ 0.05).  Collectively, these data suggest that depleting KCs DIO and 
ob/ob mouse livers is associated with decreased hepatic steatosis, which is mediated at 
least, in part, by down-regulating hepatic lipogenesis. 
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Table 3.1. Macrophage depletion by clodronate liposomes improves fasting glycemia 
and insulin levels in DIO and ob/ob mice with no changes in the metabolic profile.  
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Table 3.1. Macrophage depletion by clodronate liposomes improves fasting glycemia 
and insulin levels in DIO and ob/ob mice with no changes in the metabolic profile.  
13-week HFD-challenged WT mice or 8-week ob/ob mice were injected with 2 doses of 
clodronate liposomes (250 mg/kg) or PBS liposomes i.p. over 6 days with a 3-day 
interval.  The data is representative of 12-16 DIO and 7-10 ob/ob animals.  DIO mice 
were housed in metabolic cages prior to treatment for baseline analysis.  The animals 
were housed in metabolic cages until completion of the experiment.  EDTA plasma was 
drawn from the retro orbital sinus for serum analysis.  Metabolic cage data is 
representative of 4-6 animals.  The values represent the mean ± SEM.  An unpaired 
student’s t-test was used for comparisons between groups. * p ≤ 0.05, ** p ≤ 0.01. 
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Figure 3.8. Clodronate liposome-mediated KC depletion in DIO and ob/ob mice has 
no affect on the hepatic expression of genes involved in fatty acid oxidation.  13-
week HFD-challenged WT mice or 8-week ob/ob mice were injected with 2 doses of 
clodronate liposomes (250 mg/kg) or PBS liposomes by i.p. over 6 days with a 3-day 
interval.  The data are representative of 12-16 DIO and 7-10 ob/ob animals.  Livers were 
isolated, RNA was extracted and subjected to qRT-PCR analysis for fatty acid oxidation 
gene expression (pparα and cpt1a) in A.) DIO and B.) ob/ob mice.  The values represent 
the mean ± SEM.  An unpaired student’s t-test was used for comparisons between groups 
(n.s.). 
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Figure 3.9. Clodronate liposome-mediated KC depletion in DIO and ob/ob mice 
significantly reduces hepatic expression of genes involved in lipogenesis. 13-week 
HFD-challenged WT mice or 8-week ob/ob mice were injected with 2 doses of 
clodronate liposomes (250 mg/kg) or PBS liposomes by i.p. over 6 days with a 3-day 
interval.  The data are representative of 12-16 DIO and 7-10 ob/ob animals.  Livers were 
isolated, RNA was extracted and subjected to qRT-PCR analysis for lipogenic gene 
expression (Fasn, Acc2, Dgat, Scd1, Elov6, PPARγ, Cidea) in A.) DIO and B.) ob/ob 
mice.  C.) Protein was extracted from the DIO mouse livers and Western blot analysis 
was performed to detect Fas expression.  PBS and Clodronate samples are from the same 
film, cut due to sample separation.  D.) Relative densitometry from C.  The values 
represent the mean ± SEM. An unpaired student’s t-test was used for comparisons 
between groups. * p ≤ 0.05, *** p ≤ 0.001. 
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Clodronate liposome-mediated KC depletion reduces hepatic inflammation in DIO 
and ob/ob mice.  
Inflammasome activation and the subsequent increase of IL-1β in obesity have 
received much attention because mouse models deficient in inflammasome components 
including NLR family pyrin domain containing 3 (Nlrp3), apoptosis-associated speck-
like protein containing CARD (ASC), and caspase-1 implicate their involvement in 
obesity-induced hepatic steatosis progression (44, 76, 229, 254).  To explore the 
underlying mechanism by which macrophage depletion ameliorated hepatic steatosis, we 
analyzed inflammatory gene expression in the livers of clodronate liposome versus PBS 
liposome-treated DIO and ob/ob mice by qRT-PCR.  Consistent with macrophage 
depletion, we observed a 40%-75% reduction in the mRNA expression of pro-
inflammatory cytokines TNF-α, IL-1β, IL-1α and the Nlrp3 in the livers of clodronate-
treated DIO mice (Figure 3.10 A; p ≤ 0.001).  We observed an even more robust 65%-
72% reduction in the expression of these genes in the livers of clodronate liposome-
treated ob/ob mice compared with PBS liposome-treated ob/ob mice (Figure 3.10 B; p ≤ 
0.05).  However, no changes in the mRNA expression of IL-1α were observed in 
clodronate-treated ob/ob mouse livers (Figure 3.10 B).  Taken together, these data 
demonstrate that clodronate-liposome mediated KC depletion decreases the inflammatory 
program in steatotic livers of obese mice.  
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Figure 3.10.  Clodronate liposome-mediated KC depletion in DIO and ob/ob 
mice significantly reduces hepatic expression of genes involved in 
inflammation.  13-week HFD-challenged mice or 8-week ob/ob mice were injected 
with 2 doses of clodronate liposomes (250 mg/kg) or PBS liposomes by i.p. over 6 
days with a 3-day interval.  The data are representative of 12-16 DIO and 7-10 
ob/ob animals.  Livers were isolated, RNA was extracted and subjected to qRT-
PCR for inflammatory gene expression (TNF-α, IL-1β, IL-1α, IL-6, Nlrp3) in A.) 
DIO and B.) ob/ob mice.  The values represent the mean ± SEM.  An unpaired 
student’s t-test was used for comparisons between groups. * p ≤ 0.05, *** p ≤ 
0.001. 
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Figure 3.11.  Clodronate liposome-mediated KC depletion ameliorates hepatic 
steatosis in obese mice independently of VATM content.  A.)  DIO and ob/ob mice 
present with glucose intolerance, IR, hepatic steatosis and VATM enrichment with 
associated inflammation in both the liver and AT.  Steatosis is caused, in part, by an 
increased lipogenic program in obesity. B.)  i.p. administration of clodronate-
encapsulated liposomes depletes VATMs and KCs, improves the metabolic profile and 
ameliorates diet-induced steatosis by reducing hepatic inflammation, TG accumulation 
and lipogenic gene expression in DIO mice.  Clodronate liposome-mediated KC 
depletion in ob/ob mice improves the metabolic profile and markedly reduces hepatic 
inflammation, steatosis and lipogenic gene expression without affecting VATM content.   
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Physiological concentrations of recombinant IL-1β stimulate TG accumulation in 
isolated primary mouse hepatocytes. 
 Recent reports have implicated the involvement of the Nlrp3 inflammasome in the 
development of hepatic steatosis (44, 181, 229).  Based upon the reduced Nlrp3 and IL-
1β mRNA expression in the livers of both the DIO and ob/ob clodronate-treated mice, we 
hypothesized that IL-1β might play a key role in steatosis development in hepatocytes.  
We isolated primary hepatocytes and assessed TG accumulation after 24-hour treatment 
with recombinant IL-1β or PBS (Figure 3.12).  Microscopic evaluation revealed a dose-
dependent increase in TG accumulation with increasing physiological doses of IL-1β as 
measured by Oil-Red-O staining (Figure 3.12 A) (181).  To quantify the increased TG 
accumulation we measured total hepatocyte TGs and found a 50% increase in the 
recombinant IL-1β (10 ng/ml) treated hepatocytes compared with untreated cells (Figure 
3.12 D; p ≤ 0.001).  Western blotting revealed a 30% increase in Fas protein expression 
in the recombinant IL-1β (10 ng/ml) treated hepatocytes compared with untreated cells 
(Figure 3.12 B-C; p ≤ 0.05).  .  Taken together, these data support the hypothesis that IL-
1β promotes TG accumulation by upregulating de novo lipogenesis in primary 
hepatocytes and is important for the pathogenesis of obesity-induced steatosis. 
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Figure 3.12.  Physiological concentrations of IL-1β elicit a biological response in 
primary mouse hepatocytes to increase TG accumulation and Fas expression.  WT 
primary hepatocytes were isolated via perfusion, stimulated with the indicated doses of 
recombinant mouse IL-1β and evaluated after 24-hours.  A.) Cells were fixed in 10% 
formalin and stained with Oil-Red-O to assess TG accumulation.  B.) Fas expression was 
analyzed in primary hepatocyte cell lysates after a 24-hour stimulation with the indicated 
doses of recombinant IL-1β and normalized to β-actin. C.) Relative densitometry from B.  
D.) The total TGs were extracted and measured after a 24-hour stimulation with 
recombinant IL-1β (10 ng/mL) and normalized to the amount of total protein.  The data 
are representative of 4 experiments.  All stimulations were performed in duplicate.  
Values represent the mean ± SEM.  A paired student’s t-test was used for comparisons 
between groups * p ≤ 0.05, *** p ≤ 0.001. 
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Pharmacological blockade of the IL-1 signaling pathway ameliorates diet-induced 
steatosis in mice. 
The activity and signaling cascades downstream of IL-1α and IL-1β are tightly 
regulated by IL-1Ra, an endogenous antagonist of the IL-1 receptor (37, 40, 123).  IL-
1Ra negatively regulates IL-1 signaling by binding and blocking its receptor without 
activation, and mice lacking IL-1Ra has amplified steatosis compared with WT animals 
(101).   To directly determine whether pharmacological inhibition of IL-1 signaling has a 
protective effect against NAFLD in DIO mice, we treated mice with recombinant human 
IL-1Ra (Anakinra).  We fed mice a HFD for 9-weeks to establish IR and steatosis and 
then i.p. administered IL-1Ra (32.5 mg/kg) or an equal volume of saline daily for the 
final 32 days of a 13-week HFD challenge.  To confirm that IL-1Ra was biologically 
active in these mice, we performed intraperitoneal glucose tolerance tests (GTTs) 28 days 
after the start of injections (Figure 3.13 C-D).  Consistent with previous studies (125, 
205), IL-1Ra treatment improved glucose tolerance without affecting the total animal 
body weight in DIO mice (Figure 3.13; p ≤ 0.05).   Serum recombinant human IL-1Ra 
levels were increased in IL-1Ra-treated mice compared with saline-treated mice, 
confirming that a physiological excess of IL-1Ra was present in circulation (Figure 3.14; 
p ≤ 0.01).   
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Figure 3.13.  Pharmacological intervention via inhibition of IL-1 signaling improves 
glucose tolerance in DIO mice.   
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Figure 3.13.  Pharmacological intervention via inhibition of IL-1 signaling improves 
glucose tolerance in DIO mice. 13-week HFD-challenged WT  mice were started on 
daily injections of IL-1Ra (Anakinra; 32 mg/kg) or saline by i.p. administration at 32 
days prior to sacrifice. The data are representative of 10 mice per group.  At the end of 13 
weeks, Anakinra-treated mice displayed no changes in the A.) total animal body weight 
and were more glucose tolerant as demonstrated by the B.) IPGTT of saline (circles) and 
HFD (squares) at 13 weeks of HFD (injection day 28) with a reduced AUC that was 
calculated with a baseline correction (22731 ± 1593 vs. 19777 ± 1284 (min*mg/dL) 
n.s.).  C.) The fasting insulin levels for the IPGTT.  The values represent the mean ± 
SEM.  An unpaired student’s t-test was used for comparisons between groups. * p ≤ 0.05, 
** p ≤ 0.01. 
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Figure 3.14.  Recombinant human IL-Ra treatment results in increased serum IL-
1Ra concentrations in DIO mice.  13-week HFD-challenged WT mice were started on 
daily injections of IL-1Ra (Anakinra; 32 mg/kg) or saline by i.p administration at 32 days 
prior to sacrifice.  The data are representative of 10 mice per group.  EDTA plasma was 
drawn via the retro orbital sinus and serum was analyzed for IL-1Ra by ELISA.  The 
values represent the mean ± SEM. An unpaired student’s t-test was used for comparisons 
between groups ** p ≤ 0.01. 
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Upon dissection of the mice, a macroscopic reduction in the steatotic appearance 
of the IL-1Ra-treated mouse livers was observed compared with saline-treated mice 
(Figure 3.15 A-C).  In agreement with this observation, liver weights as a percentage of 
body weight were reduced by approximately 20% in IL-1Ra-treated mice compared with 
saline-treated mice (Figure 3.15 B). Microscopic analysis of steatosis, as assessed by 
H&E and Oil-Red-O staining, revealed a significant improvement in the liver steatosis in 
the IL-1Ra-treated animals compared with saline-treated controls (Figure 3.15 A).  To 
quantify this improvement, we measured total hepatic TGs and found a 30% reduction in 
IL-1Ra-treated mice compared with saline-treated mice (Figure 3.15 C; p ≤ 0.05).   
Importantly, these data demonstrate that inhibition of IL-1 signaling by IL-1Ra 
administration in obese mice is sufficient to reduce hepatic TG content and improve 
obesity-induced hepatic steatosis.  
To further confirm the activity of IL-1Ra in these mice, RNA was extracted from 
the livers of the IL-1Ra or saline-treated DIO mice to evaluate the mRNA expression of 
pro-inflammatory cytokines, including IL-1β and TNF-α.  There was a reduction in 
hepatic TNF-α and IL-1β, however, we observed no changes in IL-1α, IL-6 or Nlrp3 
expression in the IL-1Ra-treated mice compared with saline-treated control mice (Figure 
3.16 A; p ≤ 0.05).  To assess whether the improved steatosis in the IL-1Ra-treated mice 
was due to altered lipid metabolism, genes involved in fatty acid synthesis and fatty acid 
oxidation were analyzed.  Consistent with our previous findings in the clodronate-treated 
mice, reduced expression of genes involved in fatty acid synthesis and lipogenesis (elov6, 
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dgat, fasn, acc2) was observed in the IL-1Ra-treated mice compared with saline-treated 
control animals (Figure 3.16 B; p ≤ 0.05).  We observed no changes in the expression of 
genes related to fatty acid oxidation, such as pparα or cpt1a (Figure 3.16 C).  Taken 
together, these data demonstrate that IL-1Ra administration protects against hepatic 
steatosis to a similar extent as clodronate liposome-mediated KC depletion in obese mice.  
Importantly, these findings also suggest that IL-1 signaling plays a significant role in the 
progression of obesity-induced steatosis by activating the lipogenic pathway in 
hepatocytes.
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Figure 3.15.  Pharmacological intervention via inhibition of IL-1 signaling 
ameliorates diet-induced steatosis in DIO mice. .  13-week HFD-challenged mice were 
started on daily injections of IL-1Ra (Anakinra; 32 mg/kg) or saline by i.p administration 
at 32 days prior to sacrifice.  The data are representative of 10 mice per group.  A.) The 
livers were isolated, fixed in 10% formalin, embedded in paraffin, and stained with H&E 
or frozen in OCT and stained with Oil-Red-O to assess steatosis.  B.) The livers were 
isolated, weighed and represented as a percentage of the total animal body weight. C.) 
The total TGs were extracted and normalized to tissue weight.  The values represent the 
mean ± SEM.  An unpaired student’s t-test was used for comparisons between groups * p 
≤ 0.05, ** p ≤ 0.01. 
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Figure 3.16.  Pharmacological intervention via inhibition of IL-1 signaling reduces 
hepatic expression of genes involved in inflammation and lipogenesis in DIO mice.  
13-week HFD-challenged mice were started on daily injections of IL-1Ra (Anakinra; 32 
mg/kg) or saline by i.p administration at 32 days prior to sacrifice.  The data are 
representative of 10 mice per group.  The livers were isolated, RNA was extracted and 
subjected to qRT-PCR for expression of genes involved in A.) inflammation (TNF-α, IL-
1β, IL-1α, IL-6, Nlrp3), B.) lipogenesis (Fasn, Acc2, Dgat, Scd1, Elov6, PPARγ, Cidea) 
and C.) fatty acid oxidation (PPARα, Cpt1a).  The values represent the mean ± SEM.  An 
unpaired student’s t-test was used for comparisons between groups * p ≤ 0.05, ** p ≤ 
0.01. 
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3.4. Discussion 
The key results presented herein demonstrate that the macrophage-derived 
inflammatory mediator IL-1β potentiates the hepatic manifestation of the metabolic 
syndrome by stimulating lipogenesis and hepatic steatosis in obese mice (Figures. 3.9, 
3.11, 3.15, 3.16).  Utilizing clodronate liposomes to selectively deplete liver KCs in 
genetically obese ob/ob mice, we report remarkable amelioration of hepatic steatosis and 
significant reductions in hepatic inflammation and lipogenic gene expression (Figures 
3.7, 3.9-3.11).  Similar results were obtained in the DIO model treated with clodronate 
liposomes (Figures 3.4, 3.9-3.11).  We also show that pharmacological blockade of IL-1 
signaling by IL-1Ra dramatically improves hepatic steatosis by significantly decreasing 
inflammation and lipogenic gene expression in DIO mouse livers (Figures 3.15 and 
3.16). Taken together, these data indicate that inflammation not only drives liver disease 
progression, but also facilitates the increased lipogenic program and increased TG 
content in obese mouse livers.   
Inflammation in both VAT and liver appear to play important roles in mediating 
disrupted metabolism in obesity.  Immune activation and macrophage recruitment to 
obese AT is correlated with systemic IR and may contribute to adipocyte dysfunction 
with limited ability to sequester triglyceride and ectopic lipid deposition (7).  Lipid-laden 
KCs in the liver, resulting from increased influx of excess FFAs in circulation and 
increased hepatic DNL, are primed to recruit immune cells and exhibit a pro-
inflammatory phenotype that exacerbates hepatic inflammation and TG accumulation, 
thus promoting obesity-induced steatosis and NAFLD (129).  However, the specific role 
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of KCs in obesity-induced hepatic steatosis remains unclear because the authors of 
numerous studies on this point have come to contradictory conclusions (18, 31, 54, 124).  
For example, Bu et al, administered clodronate liposomes by i.p. as a preventative 
treatment against DIO and reported protection against diet-induced steatosis; however, 
the data show robust decreases in VATM content, but only modest reductions in KC 
content in the livers of clodronate-treated DIO mice (18).  The use of CD11c-diptheria 
toxin transgenic mice to deplete macrophages in AT revealed normalization of insulin 
sensitivity in obese mice; however, this method also did not alter KCs in the liver (179).  
Feng and colleagues reported significant improvements in obesity-induced steatosis with 
marked reductions in VATM and KC content in clodronate liposome-treated DIO mice 
(54).  On the contrary, Clemente, et al reported significant increases in both hepatic TG 
and VATM content in DIO mice treated with clodronate liposomes by i.p., and Lanthier, 
et al reported significant reductions in KCs without changes to the hepatic TG or VATM 
contents after intravenous clodronate liposome administration in DIO mice (31, 124).  
Thus, the differences in methods used amongst these studies, including dissimilar 
administration routes, inconsistent injection timelines, varied diets and feeding schedules, 
and inconsistent clodronate concentrations have confounded our understanding of the role 
of KCs in hepatic lipid metabolism.   
We approached this problem by studying both a DIO mouse model and a genetic 
mouse model of obesity.  Our studies presented here on the ob/ob mouse, which 
responded to the clodronate treatment with selective KC depletion without macrophage 
cell depletion in VAT or SAT, was particularly insightful (Figure 3.6).  This selectivity 
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of macrophage depletion of KCs but not VATMs in the ob/ob mouse may relate to an 
impaired ability of AT macrophages from ob/ob mice to take up liposomes.  Li et al 
demonstrated that lipid-laden macrophages from the peritoneum and atherosclerotic 
lesions of ob/ob mice have an impaired ability to clear apoptotic cells, suggesting a 
generalized defect in the phagocytic ability of ob/ob macrophages (130).  Additionally, 
clodronate preferentially depletes F4/80high CD11blow macrophages, consistent with the 
expression profile of KCs, whereas clodronate does not effectively deplete F4/80low 
CD11bhigh macrophages from other tissues or in systemic circulation (99, 114).  For these 
reasons, by utilizing the ob/ob mouse, we were able to characterize the metabolic 
consequences of selective KC depletion in the absence of generalized macrophage 
depletion in other tissues, providing us with a novel KC depletion system.  Thus, the 
striking improvement of obesity-induced hepatic steatosis in the clodronate-treated ob/ob 
mice reveals a profound regulation by KCs on hepatic lipid metabolism.  
Our data also revealed remarkable improvements in obesity-induced hepatic 
steatosis with reductions in liver weight and hepatic TG content in the clodronate-treated 
DIO mice when compared with PBS liposome-treated control animals (Figure 3.4).  A 
recent report by Bu et al suggests that this clodronate liposome-induced reduction of 
hepatic TGs in DIO mice is dependent upon VATM depletion (19).  In our study, cell 
depletion due to clodronate liposomes was observed for both KC and VATMs in the DIO 
mouse model (Figures 3.3 and 3.6), precluding a specific interpretation regarding which 
pool of cells may be responsible for the metabolic effects observed in this mouse model.  
However, our results in the ob/ob mouse showing a selective KC effect on hepatic lipids 
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suggests that KCs may also drive liver TG accumulation in the DIO model, and that both 
KCs and VATMs are important in modulating obesity-induced hepatic steatosis (Figure 
3.11).  
The hallmark of NAFLD is the excessive accumulation of TG in hepatocytes 
caused by alterations in hepatic lipid metabolism.  Mechanisms contributing to excessive 
hepatic TG accumulation in obesity are disruptions in lipid disposal via β-oxidation or 
VLDL secretion, but primarily due to enhanced hepatic DNL and increased FFA delivery 
to the liver (186). Increased lipolysis of expanded AT and the consequent rise in 
circulating FFAs account for 60% of the hepatic TGs in obese patients presenting with 
NAFLD (57).  Clodronate liposome-treatment reduced VATM content in DIO mice, and 
these mice present with increased circulating FFAs (Figure 3.3 A-C, Table 3.1).  These 
data are consistent with Kosteli, et al. demonstrating that macrophage cell depletion in 
VAT leads to increased expression of the TG lipase ATGL and increased lipolysis in 
mice (118).  We report no changes in circulating FFAs in clodronate-treated ob/ob mice, 
and deem this to be due to the inability to deplete VATMs in this model; however, these 
mice exhibit increased circulating TGs (Figure 3.6 A-C, Table 3.1).  Importantly, the 
rise in circulating FFAs in clodronate-treated DIO mice is accompanied by remarkable 
hepatic TG clearance without changes in the cholesterol profile, circulating ketones, or 
EE when the mice are subjected to metabolic cage analysis (Figure 3.4, Table 3.1).  
Using a multiple-stable-isotope approach, Donnelly et al. estimated de novo lipid 
synthesis accounts for 30% of the hepatic TG content in NAFLD patients (46).  We 
report reduced expression of genes related to de novo hepatic lipogenesis (Fasn, Acc2, 
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Dgat, Scd1) in both DIO and ob/ob clodronate-treated mice (Figure 3.9 A-D).  
Consistent with our data, the liver-specific Scd1 KO mice are protected from obesity-
induced hepatic steatosis, while exhibiting reduced rates of hepatic fatty acid synthesis 
and decreased expression of key lipogenic enzymes (Fasn and Acc1/2) (148).  Mao, et al 
generated liver-specific Acc1 KO mice with decreased rates of DNL; however, a 
compensatory up regulation of Acc2 occurred in other studies utilizing these mice (81, 
141).  Inhibition of Acc1/Acc2 by antisense oligonucleotides reversed diet-induced 
hepatic steatosis in mice (81, 141, 206).  Collectively, our data suggests that the clearance 
of hepatic TGs after clodronate liposome-mediated KC depletion in the livers of obese 
mice is associated with decreased hepatic steatosis which is mediated, at least in part, by 
down regulating hepatic DNL.          
Obese humans that present with NAFLD have increased circulating and hepatic 
levels of TNF-α, IL-1β, IL-6 and other acute phase proteins when compared with lean 
control subjects (45, 153, 252).  KC depletion significantly reduced hepatic gene 
expression of these pro-inflammatory cytokines in both clodronate-treated DIO and ob/ob 
mice (Figure 3.10 A-B).  We also report decreased Nlrp3 expression, an essential 
inflammasome component that is necessary for caspase-1 activation and IL-1β release, in 
both clodronate-treated DIO and ob/ob mice compared with PBS liposome-treated 
controls (Figure 3.10 A-B).  Our data also demonstrated no change in the 
inflammasome-independent cytokine IL-1α gene expression in clodronate-treated ob/ob 
mouse livers (Figure 3.10 B).  Even though clodronate-mediated KC depletion improves 
hepatic steatosis in both models, we only observe a decrease in IL-1α expression in the 
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clodronate-treated DIO mouse livers compared with control mice (Figure 3.10 A).  
Adoptive transfer experiments reveal that IL-1α is a hepatocyte-derived cytokine, rather 
than from KCs or recruited bone marrow-derived cells in obese mice (105-106).  
Furthermore, IL-1α and IL-1β are expressed at different phases of the inflammatory 
response and are derived from different cell types, suggesting that they may have distinct 
biological roles (194).  Additionally, IL-1β KO mice are protected from diet-induced 
steatosis, whereas IL-1α KO mice develop steatosis (105).  Although in our studies we 
cannot discount IL-1α involvement, we hypothesize that it does not play a role in obesity-
induced hepatic steatosis development.  Thus, the decreases in hepatic inflammation after 
clodronate liposome-mediated KC depletion suggest that inflammasome activation 
required to increase IL-1β production from KCs is important for obesity-induced hepatic 
inflammation.   
IL-1β rapidly increases hepatic lipid accumulation in vivo by acutely increasing 
the rates of hepatic fatty acid synthesis (76).  To further address the steatogenic potential 
of IL-1β, we assessed whether IL-1β would increase hepatic TG accumulation in a cell 
autonomous manner.  IL-1β treatment increased TG accumulation and expression of the 
key lipogenic enzyme, Fas, in primary hepatocytes (Figure 3.12).  In agreement with the 
decreased hepatic inflammation observed in clodronate-treated mice, caspase-1-deficient 
mice (that lack IL-1β expression) exhibit attenuated diet-induced hepatic steatosis and 
significant decreases in hepatic lipogenic gene expression compared with WT control 
mice (44).  These data suggest that IL-1β influences hepatocyte lipid metabolism in obese 
mice by stimulating the DNL pathway to drive hepatic TG accumulation.  However, 
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Stienstra and colleagues suggested that IL-1β-mediated suppression of hepatic PPARα 
and fatty acid oxidation was responsible for hepatic lipid accumulation in obesity (224).  
We report no changes in either PPARα or Cpt1a gene expression, RER, oxygen 
consumption or circulating β-hydroxybutyrate levels in clodronate-treated DIO mice 
compared with PBS liposome-treated mice, suggesting functional hepatic fatty acid 
oxidation in our clodronate-treated DIO mice (Figure 3.8 and Table 3.1).  
The inflammatory response associated with obesity arises from an activation of 
the innate immune system, concurrently increasing anti-inflammatory cytokines to 
neutralize these pro-inflammatory changes.  IL-1Ra, a naturally occurring antagonist of 
IL-1 signaling, is released as an acute phase protein and is produced by hepatocytes, 
macrophages/monocytes, and even adipocytes to balance the inflammatory affects of IL-
1α/β (65, 101, 103).  Circulating IL-1Ra positively correlates with obesity, and IL-1Ra 
KO mice exhibit a dramatic exacerbation of hepatic steatosis (101, 145).  Pioglitazone, an 
oral anti-diabetic drug, decreases hepatic steatosis and attenuates the subclinical 
inflammation in NAFLD patients; however prominent side effects include increased 
adiposity and weight gain (13, 189).  Anakinra, also used as a therapeutic in obese, 
diabetic patients, improves pancreatic islet function and glucose tolerance, but has not 
been studied in the context of NAFLD (45).  We demonstrated here that pharmacological 
blockade of IL-1 signaling by IL-1Ra administration is sufficient to improve hepatic 
steatosis and the metabolic profile in DIO mice (Figures 3.13-3.16).  Daily IL-1Ra 
administration to DIO mice significantly improved glucose tolerance as detected by 
IPGTT without changes to the total animal body weight (Figure 3.13 A-C).   
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Collectively, we report a significant improvement in obesity-induced steatosis as assessed 
by hepatic Oil-Red-O staining, decreased liver weight and reductions in the hepatic TG 
content of IL-1Ra-treated mice compared with saline-treated control mice (Figure 3.15).  
The expression of pro-inflammatory cytokines and genes involved in fatty acid synthesis 
(Fasn, Dgat, Scd1) are reduced significantly in the livers of IL-1Ra-treated mice, thus 
confirming our findings in the clodronate-treated DIO and ob/ob mouse models (Figure 
3.9 and Figure 3.10).  Importantly, inhibition of IL-1 signaling did not affect fatty acid 
oxidation gene expression (Figure 3.16 C).  These data suggest that inhibition of IL-1 
signaling by IL-1Ra administration is sufficient to improve obesity-induced hepatic 
steatosis by decreasing hepatic lipogenic gene expression and TG accumulation in DIO 
mouse livers.  
In summary, our findings demonstrate that KC depletion in two mouse models of 
obesity markedly reduces hepatic inflammation and obesity-induced steatosis.  With 
selective depletion of KCs in the ob/ob mouse, our data suggests that this improvement in 
hepatic steatosis is independent of VATM depletion (Figure 3.11), and that KCs and KC-
derived cytokines, including IL-1β are important for hepatic metabolism regulation.  Our 
data also suggests that the significant reduction in hepatic TGs observed in both 
clodronate-treated DIO and ob/ob mice is mediated, in part, by down regulating hepatic 
inflammation and DNL.  Additionally, we report that inhibition of IL-1 signaling by 
administration of IL-1Ra markedly improves hepatic steatosis in DIO mice by 
significantly reducing hepatic inflammation and lipogenic gene expression (Figure 3.17).  
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Therefore, the results herein suggest that IL-1β signaling mediates hepatocyte TG 
accumulation by driving the de novo lipogenic signaling pathway in obese mouse livers 
and that IL-1β represents a promising therapeutic target in the treatment of obesity-
induced NAFLD. 
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Figure 3.17.  Pharmacological blockade of IL-1 signaling by IL-1Ra administration 
ameliorates hepatic steatosis in DIO mice.  IL-1β elicits a biological response to 
increase hepatocellular TG accumulation and Fas protein expression in a cell autonomous 
manner ex vivo.  This was confirmed in vivo by daily i.p. IL-1Ra administration to 
glucose intolerant DIO mice for 32 days.  Mice have marked reductions in hepatic TG 
accumulation, lipogenic gene expression and inflammation accompanied by significant 
metabolic improvements determined by GTT. 
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3.5. Experimental Procedures 
 
Animals, Diets and Treatments 
Wild type male C57Bl/6J and ob/ob mice were purchased from Jackson laboratories (Bar 
Harbor, ME).  Animals were fed ad libitum with free access to water and housed in the 
University of Massachusetts Medical School (UMASS) Animal Medicine facility with a 
12:12-h light-dark cycle.  Animals were weighed weekly for the duration of the diet 
study.  Animals utilized for the clodronate-encapsulated liposome and IL-1Ra studies 
were fed a HFD (45 kcal% fat; D12451; Research Diets) starting at 4 wks of age for 13-
14 weeks.  8-week-old ob/ob mice were fed a standard chow diet (LabDiet PicoLab 
5053).  Liposome-encapsulated clodronate (250 mg/kg) or an equivalent volume of PBS-
liposomes was administered twice intraperitoneally (i.p.) with a three day interval over 
the course of 6 days the final week of the HFD-challenge.  Mice were started on daily i.p. 
injections of recombinant human IL-1Ra (32 mg/kg) or saline (Anakinra; Amgen) 
starting after 9 weeks of HFD and 32 days prior to sacrifice.  IPGTTs were performed as 
previously described after 28 daily IL-Ra injections (265).  Measurements of EE, RER, 
indirect calorimetry, and physical activity using metabolic cages (TSE Systems, Bad 
Homburg, Germany) were performed by the UMass Mouse Metabolic Phenotyping 
Center.   At experimental completions, mice were fasted for 6 hours at the start of the 
light cycle and then euthanized with CO2 inhalation and cervical dislocation.  All of the 
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experiments were performed in accordance with protocols approved by the Institutional 
Animal Care and Use Committees (IACUC) at UMass Medical School. 
Sample Storage 
Liver and VAT were harvested and snap frozen in liquid nitrogen for RNA and protein or 
OCT for Oil-Red-O analysis.  Blood was drawn via the retro-orbital sinus into EDTA 
tubes; plasma was centrifuged at 10,000 rpm for 10 min and aliquotted.  All of the 
samples were stored at -80C.     
 
Primary cell isolation and culture 
Anesthetized 8-week old WT mice were perfused via the inferior vena cava as previously 
described (15).  Briefly, mice were perfused with a 0.5 mM EGTA solution followed by 
enzymatic collagenase digestion (Sigma) in 1mM CaCl2.  Hepatocytes were washed with 
1mM CaCl2 (3x) and separated by centrifugation.  Primary hepatocytes were seeded in 6-
well plates.  Before starting stimulation experiments, hepatocytes were rested for 3 hours 
in M199 media containing 1% Penicillin/Streptomycin, 10% FA-free BSA, 2% FBS, 
Dexamethasone (100uM), and Insulin (100nM) at 37 °C and 5% CO2.  Subsequently, 
culture media was replaced and cells were maintained in M199 media containing 
Penicillin/Streptomycin, Dexamethasone and Insulin.  Insulin was present in all 
experimental media to maintain the health of the primary cultures.  Cells were left 
untreated or treated with 10 ng/ml recombinant IL-1β (Millipore) for 24 hours. 
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RNA isolation and quantitative RT-PCR 
Liver and VAT were isolated, snap frozen in liquid nitrogen, and stored at −80°C.  
Tissues were homogenized using the gentleMACs Dissociator (Miltenyi Biotec) and 
isolated following the manufacturers protocol (TriPure, Roche).  Precipitated RNA was 
treated with DNAse (DNA-free, Life Technologies) prior to reverse transcription (iScript 
Reverse transcriptase, BioRad).  SYBR green quantitative PCR (iQ SYBR green 
supermix, BioRad) was performed on the BioRad CFX97.  Gene expression was 
normalized to the ribosomal gene 36B4 and expressed relative to the expression of PBS 
liposome- or saline-treated mice.  The internal loading control, 36B4, did not change with 
liposome or IL-1Ra treatment.  Melt curve analysis was performed to determine the PCR 
reaction product specificity.  Primer sequences were designed with Primer Bank.  Primer 
sequences are as follows: 36B4: 5’- TCCAGGCTTTGGGCATCA-3’, 3’- 
CTTTATCAGCTGCACATCACTCAGA-5’, CD11c: 5’- 
CTGGATAGCCTTTCTTCTGCTG-3’,3’- GCACACTGTGTCCGAACTCA-5’; F4/80: 
5’- CCCCAGTGTCCTTACAGAGTG-3’, 3’- GTGCCCAGAGTGGATGTCT-5’; IL1β: 
5’- GCAACTGTTCCTGAACTCAACT-3’, 3’- ATCTTTTGGGGTCCGTCAACT-5’; 
TNFα: 5’-CAGGCGGTGCCTATGTCTC-3’, 3’-CGATCACCCCGAAGTTCAGTAG-
5’; IL-6: 5’- TAGTCCTTCCTACCCCAATTTCC-3’, 3’- 
TTGGTCCTTAGCCACTCCTTC-5’; IL-1α: 5’- GCACCTTACACCTACCAGAGT-3’, 
3’- TGCAGGTCATTTAACCAAGTGG-5’;  NLRP3: 5’- 
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ATTACCCGCCCGAGAAAGG-3’, 5’-TCGCAGCAAAGATCCACACAG-3’, FASn: 
5’-GGAGGTGGTGATAGCCGGTAT-3’, 5’-TGGGTAATCCATAGAGCCCAG-3’, 
DGAT: 5’- TCCGTCCAGGGTGGTAGT-3’, 5’- 
TGAACAAAGAATCTTGCAGACGA-3’, ELOV6: 5’- 
GAAAAGCAGTTCAACGAGAACG-3’, 5’- AGATGCCGACCACCAAAGATA-3’, 
ACC2: 5’- GGAGGCTGCATTGAACACAAGT-3’, 5’- 
TGCCTCCAAAGCGAGTGACAAA-3’, PPARG2: 5’- 
ATGGGTGAAACTCTGGGAG-3’, 5’- GTGGTCTTCCATCACGGAGA-3’, SCD1: 5’-
TTCTTGCGATACACTCTGGTGC-3’, 5’-CGGGATTGAATGTTCTTGTCGT-3’, 
PPARα: 5’-AGAGCCCCATCTGTCCTCTC-3’, 5’-
ACTGGTAGTCTGCAAAACCAAA-3’, CPT1A: 5’-
GCTGCTTCCCCTCACAAGTTCC-3’, 5’-GCTTTGGCTGCCTGTGTCAGTATGC-3’, 
BAX: 5’-AGACAGGGGCCTTTTTGCTAC-3’, 5’-AATTCGCCGGAGACACTCG-3’,  
BAK: 5’-CAGCTTGCTCTCATCGGAGAT-3’, 5’-
GGTGAAGAGTTCGTAGGCATTC-3’ 
 
Protein Analysis 
Tissue pieces were homogenized in a Dounce homogenizer in RIPA protein lysis buffer 
[50 mM Tris (pH 7.4), 0.1% SDS, 400 mM NaCl, 0.5% deoxycholate, 1% NP40,1 mM 
EDTA, 25 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM benzamidine, 1 mM 
phenylmethylsulfonyl fluoride, and 10 μg/ml of aprotinin and leupeptin. Primary 
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hepatocytes were homogenized in lysis buffer (150 mM NaCl, 2% SDS, and 2mM 
EDTA, 25 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM benzamidine, 1 mM 
phenylmethylsulfonyl fluoride, and 10 μg/ml of aprotinin and leupeptin.  Samples were 
sonicated using a microtip and protein content was quantified using a BCA protein assay 
kit (Thermo Scientific).  Proteins were resolved on a 10% SDS-PAGE gel, transferred to 
a nitrocellulose membrane, blocked with 5% non-fat milk in TBST (0.05% Tween 20 in 
Tris-buffered saline), washed with TBST, and incubated with primary antibodies 
overnight.  The blots were washed with TBST, and a horseradish peroxidase secondary 
antibody was applied. Proteins were visualized using Western Lightening Plus ECL 
(PerkinElmer).  Primary antibodies used were Fas and β-Actin (Cell Signaling; 1:1000 
and 1:10,000).  
 
Histology 
Livers were isolated and fixed in 10% formalin, paraffin embedded, and stained with 
hematoxylin and eosin (H&E) or frozen in OCT and stained with Oil-Red-O.  Images 
were taken with an Axiovert 35 Zeiss microscope (Zeiss, Germany) equipped with an 
Axiocam CCl camera at 10x or 20x magnification. 
 
Non-Esterified Fatty Acid (NEFA) measurements 
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EDTA plasma was collected from the retro-orbital sinus after isoflurane anesthesia.  
NEFA were measured with a colorimetric assay (WAKO) using the manual procedure 
according to manufacturer’s instructions. 
 
Triglyceride measurements 
Total hepatic TG content measurement was performed as previously described (60). 
Briefly, total lipids were extracted from liver samples (100 mg) or primary hepatocyte 
cultures using a 2:1 mixture of chloroform and methanol. The organic layer was dried 
overnight and reconstituted in a solution containing 60% butanol and 40% of a 2:1 
mixture of Triton-X114 and methanol.  Total TGs were measured with a colorimetric 
assay (Sigma) using the manual procedure according to manufacturer’s instructions. 
 
ELISA Assay 
EDTA plasma was collected from the retro-orbital sinus after isoflurane anesthesia.  The 
exogenously administered IL-1Ra was measured using specific ELISA recognizing 
human IL-1Ra (R&D systems Inc.) and fasting insulin levels using a rat/mouse insulin 
ELISA (Millipore).  Both assays were measured in duplicate and according to the 
manufacturers′ instructions.  
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Flow cytometry 
The VAT SVF was isolated by digestion in HBSS, 2.5% BSA and 2 mg/mL collagenase 
for 45 minutes and strained through a 70 μm filter followed by red blood cell lysis.  Cells 
were blocked with mouse IgG in FACS buffer (1% BSA/PBS).  Cells were stained with 
antibodies directed towards F4/80 (APC, ABD serotec), CD11b (Percp 5.5, BD), Siglec F 
(PE, BD) and CD11c (V450, BD).  The data were collected on an LSRII (BD) and were 
analyzed with FlowJo software.  Samples were gated for scatter and single cells.  Gates 
were drawn based on fluorescence minus one (FMO) controls.  A total of 100,000 events 
were recorded.  
 
Liposome Preparation 
Cholesterol (16mg) and phosphatidylcholine (172 mg) (Sigma-Aldrich) were dissolved in 
chloroform in a round-bottom flask.  The chloroform was evaporated at 37°C in a rotary 
evaporator under vacuum until a thin lipid film formed.  2 g of 
dichloromethylenediphosphonic acid disodium salt (clodronate) (Sigma-Aldrich) were 
dissolved in 10 ml of PBS.  The clodronate-PBS solution or the control-PBS solution was 
added to the lipid film and shaken at 4 g for 30 minutes.  The solution was sonicated for 2 
minutes at room temperature in a water bath sonicator (150 watts).  The liposomes were 
washed and centrifuged at 20,000 g for 2 hours, and resuspended in 8 ml of PBS.  An 
aliquot of each liposome preparation was subjected to 1:2 phenol:chloroform extraction 
to determine the incorporated clodronate concentration within the liposomes and 
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analyzed via liquid chromatography mass spectroscopy on a Waters Acquity UPLC with 
a Phenomenex 2.1 x 100mm Synergi 4u Polar-RP 80A column.  A standard curve was 
created using QuanLynx and samples were then quantified against this calibration curve.   
 
Statistical Analysis 
All of the values are presented as the mean ± SEM.  For all experiments a student’s t-test 
for two-tailed distributions with equal variances was used for comparison between 2 
groups.  Differences less than p < 0.05 were considered to be significant.  The AUC for 
the IPGTT was calculated using a student’s t-test after performing a baseline correction 
for the basal glucose values for each individual mouse.  All of the data were entered into 
Microsoft Excel, and statistical analyses were performed with Graph Pad Prism 5.0. 
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IV:  CONCLUSIONS AND FUTURE DIRECTIONS 
 
4.1. Summary of Aims 
One of the major underlying mechanisms leading to obesity-induced IR is 
adipocyte and macrophage dysfunctions.  As previously mentioned, AT is the 
physiological site for lipid storage and essential in maintaining systemic glucose 
homeostasis, which is reinforced by the fact that lipodystrophic humans and mice are also 
IR (77, 88, 150).  Thus, impairments in AT function including the dysregulation of the 
lipogenesis-lipolysis balance and the synthesis and secretion of insulin sensitizing 
endocrine hormones reflects changes not only in AT, but systemic insulin sensitivity.  
Furthermore, hepatic IR occurs as a consequence of adipocyte dysfunction as the liver 
becomes a reservoir for AT-derived FAs, leading to NAFLD and exacerbating the MS.  
In combination with alterations in lipid metabolism, macrophage-derived inflammation 
has been linked to the progression of obesity-induced IR in obese humans and mice (55, 
82, 252).  As a result, the perception and understanding of metabolism and immunology 
have evolved largely in parallel and have led to the discoveries described herein.  Thus, 
the goals outlined for this thesis were to not only to better understand the roles of 
macrophages within AT and liver, but how they affect the essential processes necessary 
to maintain metabolic homeostasis, specifically lipid metabolism. 
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4.2. The Complex Roles of Adipose Tissue Macrophages 
In Chapter II of this thesis, we established that VAT responds differently to DIO 
than SAT, because our data demonstrates that SAT is resistant to both HFD-induced 
inflammation and macrophage infiltration by genomic and qRT-PCR analysis.  This is 
consistent with studies reporting that obese patients with increased SAT stores in the 
lower extremities remain IS, whereas VAT expansion and measures of waist 
circumference are correlated with increased risk for IR and T2DM (218).  We also 
demonstrated that although DIO mouse VAT is enriched for macrophage-specific gene 
expression, the VAT inflammatory profile was surprisingly proportional to macrophage-
specific genes (F4/80, CD68, CD11b, and CD11c) indicating that the obesity-induced 
expansion of the ATM population occurs without activation to an M1 state.  The 
genomics analysis determined that DIO mouse VAT inflammatory gene expression was 
unchanged even though the macrophage-specific marker genes were significantly 
elevated, which was particularly insightful because we discovered a discrepancy in our 
biased way of thinking and encouraged our endeavor to confirm previous reports 
attributing obese AT inflammation to M1 polarized VATMs.  We used macrophage 
marker genes like F4/80 and CD11c as reference genes in qRT-PCR analysis of VAT as a 
strategy to distinguish between two possible outcomes: increased activation or 
recruitment of M1 polarized macrophages or recruitment or expansion of the macrophage 
population occurs without activation.  Increased activation of VATMs should 
demonstrate disproportionately higher expression of inflammatory markers (TNF-α, IL-6, 
IL-1β) compared to these macrophage marker genes, like F4/80.  On the other hand, if 
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recruitment or expansion of the macrophage population occurs without activation, we 
would expect proportionate increases in both categories of markers.  Relative to 36B4 or 
cyclophilin B expression, our data coincided with the vast literature reporting significant 
increases in DIO mouse VAT inflammatory gene expression.  Surprisingly, when 
expressed relative to macrophage marker genes and not standard housekeeping genes, 
this increased inflammatory profile was abrogated and proportional to the expression of 
macrophage markers indicating that VATMs are not activated. 
Although our study was not designed to characterize ATM polarization, we 
sought to confirm previous ATM expression profiles that suggest that obesity polarizes 
ATMs toward a M1 activation state (135, 137).  Because macrophage populations present 
in lean AT display characteristics of those involved in tissue repair and remodeling, we 
hypothesized that macrophages recruited to obese AT are not driving inflammation, but 
serve an alternative function to maintain AT homeostasis and integrity under conditions 
of metabolic stress (26, 63).  Thus, we hypothesized that the relative inflammatory 
changes observed in VAT may be due to quantitative increases in macrophage content 
rather than qualitative changes in M1 polarization in DIO mouse VATMs.  For example, 
if macrophage content increases 10-fold, then the order of magnitude change in cytokine 
expression should also increase 10-fold.  Thus, when inflammatory genes are expressed 
relative to ubiquitously expressed housekeeping genes, the increased inflammatory 
signature of obese VAT will be significant and when expressed relative to macrophage 
genes, the inflammatory changes will be proportional to these genes.  A recent 
publication by Xu et al. confirmed our hypothesis by the meticulous analysis and 
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characterization of purified ATMs in multiple obese mouse models.  This study used 
expression microarrays to generate transcription profiles of VATMs from lean WT and 
ob/ob mice comparing CD11c+ and CD11c- VATM transcriptomes (262).  The authors 
did not observe immune or inflammatory pathway enrichment in either population, and 
TNF-α, IL-1β and other classical inflammatory genes had reduced rather than increased 
expression of CD11c+ VATMs (262).  Interestingly, they discovered an obesity-induced 
program of lysosome biogenesis and their data suggest that secreted factors, including 
AT-derived lipids, induce a program in which lipid uptake and lysosomal biogenesis are 
coordinately regulated (262).  In our clodronate liposome experiments, we observed 
significantly increased serum FFA levels in VATM-depleted DIO mice, which is 
consistent with the idea that ATMs facilitate lipid sequestration from the circulation.  
Taken together, these findings enhance the current paradigm depicting ATMs solely as 
inflammatory cells, to a colony of ATMs that consist of many subpopulations that 
mediate many functions within obese AT aside from inflammation.  These data provide 
insight to focus our studies on trophic macrophage functions including macrophage 
population involvement in tissue remodeling, angiogenesis regulation, lipid sequestration, 
and other non-inflammatory roles in the context of obesity and IR (22, 118, 177, 188, 
227).  
The data herein provide insight that although ATMs have been labeled as 
mediators of IR, it is likely that macrophages exert a multitude of effects on adipocyte 
physiology that are dependent upon the tissue microenvironment.  To address the 
complex roles of ATMs, our laboratory has developed GeRPs, an in vivo siRNA delivery 
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system that targets VATMs in obese mice (7-8).  Recently, our laboratory has 
demonstrated that GeRP-mediated selective silencing of VATM LPL decreases ATM 
foam cell formation and exacerbates glucose intolerance in genetically obese mice 
(Aouadi, M. et al; submitted).  These data demonstrate that the lipid buffering ability of 
ATMs has a profound impact on systemic glucose tolerance by their ability to sequester 
excess lipids in obese mouse VAT.  Via GeRP-mediated silencing technology, our 
studies can assess the direct roles of lipid uptake, fatty acid esterification and synthesis, 
lysosome biogenesis, and other functions that may illustrate the ATM-mediated impact 
on systemic glucose tolerance and adipocyte biology in obese mouse models.  A recently 
developed novel assay to image tumor-associated collagen turnover has discovered M2-
macrophage mannose-receptor (CD206)-dependent collagen internalization (139).  One 
approach to studying the multi-functional roles of ATMS may include collagen turnover 
imaging in combination with GeRP-mediated silencing of CD206 or extracellular matrix 
remodeling proteins in DIO mouse VATMs to determine their involvement in obese AT 
remodeling and collagen degradation.   
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4.3. KCs Regulate Hepatic Lipid Metabolism 
In Chapter III of this thesis we used clodronate liposome-mediated macrophage 
depletion to confirm published data and determine the mechanism of ATM-mediated 
lipid metabolism dysregulation in obesity.  Surprisingly, our project took an exciting turn 
and we discovered that the ob/ob mouse provides the ability to study the effects of 
macrophage depletion on KCs without affecting VATM content.  We established in vivo 
that clodronate liposome-mediated KC depletion, regardless of VATM content in both 
DIO and ob/ob mice, abrogated hepatic steatosis by reducing hepatic de novo lipogenic 
gene expression.  The observed reductions in hepatic inflammation in macrophage 
depleted obese mice led to the hypothesis that IL-1β may be responsible for obesity-
induced increased hepatic TG accumulation.  We determined that IL-1β treatment 
increases FAS protein expression and TG accumulation in primary mouse hepatocytes.  
IL-1Ra administration recapitulated these results by reducing hepatic TG accumulation 
and lipogenic gene expression in DIO mice.  Thus, these data highlight the importance of 
the inflammatory cytokine IL-1β in obesity-driven hepatic steatosis and suggests that 
liver inflammation controls hepatic lipogenesis in obesity.   
In parallel to the studies described herein, several studies have also investigated 
the role of KCs in hepatic inflammation and steatosis in obese mice.  These studies used 
anti-inflammatory drug administration, macrophage depletion strategies and bone-
marrow transplantation in combination with mice deficient in inflammatory genes (9, 31, 
54, 105, 179, 181, 224).  Taken together, it is understood that both KCs and hepatic 
inflammation regulate hepatocyte lipid metabolism but the inconsistencies in published 
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data confound our understanding of the KC-mediated regulation of diet-induced hepatic 
steatosis.  As described in the discussion section of Chapter III, the abundant usage of 
macrophage depletion strategies in the literature provides a pandemonium of conclusions, 
partially because each study addressed the KC-induced modulations of hepatic lipid 
metabolism under different conditions.  The administration route of the liposomes is 
pertinent to draw conclusions because this affects particle biodistribution and determines 
the liposome-mediated impact on macrophage populations in all tissues, including the 
liver and AT.  Additionally, the distinct kinetics and temporal patterns of hepatic TG 
accumulation in HFD-challenged mice are dependent upon the fat content and feeding 
duration (6, 67).  Thus, with variations of these parameters taken into account, it is 
difficult to draw conclusions regarding the role of KCs in hepatic lipid metabolism.  On 
the contrary, immune cells also infiltrate the liver, which upregulates hepatic 
inflammation and progression of obesity-induced NALFD to NASH (2).  By targeting 
KCs using a novel system in ob/ob mice we demonstrated that KCs are mediators of 
hepatic inflammation and steatosis, which are both causal to obesity-induced hepatic IR.   
To this end, future endeavors to extend the current studies described herein will 
utilize a novel method to target KCs in vivo and address the specific role of IL-1β in 
hepatic lipid metabolism in the context of obesity-induced hepatic steatosis.  Our 
laboratory has recently developed a method to directly target KCs in vivo via intravenous 
GeRP-mediated siRNA delivery (Tencerova, M. et al; submitted).  Using this system, IL-
1β siRNA could be administered to both DIO and ob/ob mice to confirm our findings in 
macrophage depleted and IL-1Ra-treated DIO mice, and provide a novel system to study 
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the mechanism whereby IL-1β regulates hepatic Fas expression.  Preliminary data 
suggest that hepatic inflammation may affect intrahepatocellular citrate concentrations, 
thus providing a substrate for DNL.   Furthermore, the specific silencing of KC-derived 
IL-1β will allow us to address functional questions and quantitatively measure hepatic 
lipogenic capacity in the absence of IL-1β in vivo.  Lastly, IL-1Ra can ameliorate 
alcohol-induced fatty liver, which provided a foundation for our study to expand upon 
these findings.  Our study reveals therapeutic implications for pharmacological inhibition 
of IL-1 signaling by providing a platform for IL-1Ra in obesity-induced NAFLD 
treatment.  The broader therapeutic implications of IL-1Ra may be in hepatitis C virus 
(HCV) prevention by attenuating viral replication via IL-1Ra-induced reductions in 
hepatic FA biosynthesis (27, 87).  In theory, decreased hepatic FA biosynthesis would 
reduce the enzyme activity and substrate availability that are necessary to construct viral 
particle bilayers, thus attenuating HCV replication and progression.   
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4.4. Future Work and Therapeutic Implications 
The projects described herein study the complex roles of ATMs and KCs in 
modulating lipid metabolism in metabolic disease.  The studies described above 
complement each other because VAT and liver are both anatomically linked and are 
essential in IR and metabolic disease progression.  Expansion of VAT in humans 
contributes to the increased hepatic FFA delivery derived from increased AT lipolysis, 
thus driving hepatic steatosis and IR (161).  Furthermore, exposure of KCs to dietary and 
adipocyte-derived FAs stimulates canonical inflammatory signaling cascades and 
cytokine upregulation, and negatively effects insulin signaling and hepatic glucose 
metabolism, thus providing a substantial link connecting both adipocyte lipid metabolism 
dysregulation with alterations in hepatic insulin sensitivity. 
Macrophages are present in all tissues of the body and display tremendous 
heterogeneity with diverse phenotypes and functions that are reflective of their local 
metabolic and immune microenvironment (140, 142).  The correlation between AT 
inflammation and IR and T2DM progression in obese mice and humans demonstrates a 
pathogenic role of ATMs, but there is no direct and concrete evidence proving that ATMs 
or other tissue macrophages act as pathogenic mediators in IR and T2DM (56, 196, 252, 
261).  Although our studies don’t address this issue per se, the above findings have led to 
many new questions and directions for further research studying the complex roles of 
macrophages in obesity and metabolic disease.  The discoveries made herein provide new 
insight and appreciation for the multi-functional nature of macrophages and support the 
conclusion that the roles of macrophages in obesity are not are not a simple distinction 
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between alternative and classical activation: the complex roles of macrophages in 
obesity-induced IR are not black and white.   
Our data and recent publications provide evidence that ATMs serve a multitude of 
functions within obese AT not only as drivers of IR, but also as responders to aid and 
protect adipose tissue function in obesity as we and others report an immune response 
that is reflective of the increased ATM content in DIO mouse VAT.  Many attempts have 
been made to block the macrophage infiltration into obese AT, but recent literature 
provides evidence that local macrophage proliferation and macrophage retention 
mechanisms may also be responsible for the increased ATM content that occurs in 
obesity (1, 191).  Thus, instead of blocking macrophage enrichment it may be better 
suited to study the purpose of these macrophages to enhance our understanding of their 
presence and function within the obese VAT.  To this end, our findings do not conflict 
with the abundant literature supporting the current model that inflammatory gene 
expression in obese AT modulates metabolic function, but bring awareness to the study 
of immunometabolism.  Immune and metabolic studies combined have successfully 
reversed glucose intolerance in the context of obesity by the vast use of systemic and 
cell-type specific gene depletion methods, systemic cell-type ablation, and transgenic 
overexpression in combination with dietary manipulation and drug administration in 
thousands of animal models of immune and metabolic disease.  On the other hand, our 
understanding of T2DM as an inflammatory disease remains unclear and is unable to 
fully transcend into clinical therapeutics.   
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Much clinical success has been achieved with TZD administration to promote 
insulin sensitivity in obese T2DM patients by increasing adipocyte lipid storage capacity 
(149, 209).  TZD treatments also reduce ATM content with a corresponding decrease in 
inflammatory gene expressions in obese human and mouse AT (36, 261).  Surprisingly, 
the established connection between adipocyte dysfunction, immune cell-derived 
inflammation and IR has been confounded by the less than spectacular success observed 
with anti-inflammatory drug trials in humans.  Several trials attempted to neutralize TNF-
α and failed to reduce hyperglycemia in T2DM patients or improve insulin sensitivity in 
obese IR patients (169, 178).  It is important to note the limitations of these studies 
because they used single injections, small sample sizes and failed to demonstrate 
attenuated TNFα action, thus impacting the ability to draw proper conclusions.  
Converesly, human trials involving IL-1Ra or salsalate administration have demonstrated 
promising results by reducing systemic markers of inflammation and improving insulin 
sensitivity and glucose control in obese individuals, thus supporting the roles of 
inflammation in obesity-induced IR (59, 71, 125, 196).  IL-1Ra is currently being 
administered to over-weight T1DM patients who lack residual β-cell function.  This study 
will address the direct effects of anti-inflammatory treatment on systemic insulin 
sensitivity without affects on β-cell properties (Trial #NCT01285245).  Taken together, 
these data raise many clinically critical questions that will require carefully designed 
longitudinal clinical studies to further our understanding of T2DM as an inflammatory 
disease.   
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To this end, the studies described herein provide clinical implications for anti-
inflammatory therapy as we demonstrate the complexities of macrophage-mediated 
functions in insulin sensitive tissues and the role of inflammatory cytokine IL-1β in 
hepatic lipid metabolism modulation and systemic glucose tolerance in DIO mice, which 
is reversed via IL-1Ra intervention.  The use of anti-inflammatory therapy to ameliorate 
obesity-associated NAFLD was perhaps the most important contribution to this body of 
work and is full of promise for future clinical application.  It is likely that the future of 
therapeutics will be multi-faceted and combine therapeutic approaches to enhance 
glucose tolerance and overall health in obese, IR and T2DM patients.   
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